լи
Back to
Professor Elgene Lim

Professor Elgene Lim

Professor

03/10

Post Doctorate

Cancer Biology

Dana-Farber Cancer Institute (DFCI), Harvard Medical School, Boston, USA

02/10

PhD

Molecular Biology

Walter & Eliza Hall Institute of Medical Research (WEHI), Melbourne University, Australia

12/06

FRACP

Internal Medicine & Medical Oncology

Royal Australasian College of Physicians (RACP), Australia

12/95

MBBS

Medicine & Surgery

Melbourne University, Victoria, Australia
Medicine & Health
School of Clinical Medicine

Elgene was awarded his medical degree from the University of Melbourne. He obtained his medical oncology fellowship from the Royal Australasian College of Physicians in 2006, and subsequently embarked on a PhD as a National Breast Cancer Foundation Scholar at the Walter & Eliza Hall Institute with eminent Australian breast cancer researchers Professors Jane Visvader & Geoffrey Lindemann. His research identified the aberrant cells in carriers of the BRCA1 mutant gene, a hereditary breast cancer syndrome, which are the likely culprit cells giving rise to breast cancer. He furthered his research and clinical training at the Dana-Farber Cancer Institute and Harvard Medical School under the mentorship of internationally acclaimed leaders in breast cancer research Professors Eric Winer & Myles Brown, through fellowships from the Fulbright Foundation, National Health & Medical Research Council of Australia, and Royal Australasian College of Physicians.He was awarded the National Breast Cancer Foundation Practitioner Fellowship in 2014 and returned from Boston to Australia. In 2017, he was awarded the inaugural National Breast Cancer Foundation Endowed Chair.

Elgenecurrentlyheads the breast oncology services at the Kinghorn Cancer Centre, St Vincent’s Hospital in Sydney.He also heads the Connie Johnson breast cancer research laboratory at the Garvan Institute of Medical Research. His laboratory performs clinically focused laboratory research, including the establishment of patient-derived breast tumour xenografts in mice, the evaluation of novel therapies in these preclinical breast cancer models and the comparative study between normal and breast cancer tissue. Another major focus of my group is hormone receptors (such as the estrogen and androgen receptors) in breast tumours, specifically to identify ways to sensitize these cancer cells to endocrine therapies.Their research is funded through Cancer Australia, NHMRC, Cancer Council NSW,the National Breast Cancer, Love Your Sister, St Vincent's Curran, Balnaves and Garvan foundations.
Phone
02 9355 5823
E-mail
e.lim@garvan.org.au
Location
The Kinghorn Cancer Centre 370 Victoria Street Darlinghurst NSW 2010
  • Book Chapters | 2020
    Cohen-Hallaleh RB; Rickard M; Lim E; Raymond WA; Segara D; Arnold L; Lee AHS; Schmitt FC; Field A, 2020, 'Clinical Management', in In The International Academy of Cytology Yokohama System for Reporting Breast Fine Needle Aspiration Biopsy Cytopathology Atlas
    Book Chapters | 2020
    Field AS; Raymond WA; Rickard MT; Arnold L; Brachtel EF; Chaiwun B; Chen L; Chong PY; Di Bonito L; Hoda RS; Kurtycz DFI; Lee AHS; Lim E; Ljung BM; Michelow P; Osamura RY; Pinamonti M; Sauer T; Segara D; Tse GM; Vielh P; Schmitt F, 2020, 'The International Academy of Cytology Yokohama System for Reporting Breast Fine Needle Aspiration Biopsy Cytopathology: Introduction and Overview', in The International Academy of Cytology Yokohama System for Reporting Breast Fine Needle Aspiration Biopsy Cytopathology, pp. 1 - 9,
    Book Chapters | 2019
    Saunders C; Jassal S; Lim E, 2019, 'Breast Cancer: The facts', in Breast Cancer: The Facts, Oxford University Press
    Book Chapters | 2015
    Lim E; Goel S; Winer EP, 2015, 'Adjuvant chemotherapy in breast cancer', in Breast disease: Comprehensive management, pp. 335 - 351,
  • Journal articles | 2024
    Achinger-Kawecka J; Stirzaker C; Portman N; Campbell E; Chia KM; Du Q; Laven-Law G; Nair SS; Yong A; Wilkinson A; Clifton S; Milioli HH; Alexandrou S; Caldon CE; Song J; Khoury A; Meyer B; Chen W; Pidsley R; Qu W; Gee JMW; Schmitt A; Wong ES; Hickey TE; Lim E; Clark SJ, 2024, 'The potential of epigenetic therapy to target the 3D epigenome in endocrine-resistant breast cancer', Nature Structural and Molecular Biology, 31, pp. 498 - 512,
    Journal articles | 2024
    Filipe EC; Velayuthar S; Philp A; Nobis M; Latham SL; Parker AL; Murphy KJ; Wyllie K; Major GS; Contreras O; Mok ETY; Enriquez RF; McGowan S; Feher K; Quek LE; Hancock SE; Yam M; Tran E; Setargew YFI; Skhinas JN; Chitty JL; Phimmachanh M; Han JZR; Cadell AL; Papanicolaou M; Mahmodi H; Kiedik B; Junankar S; Ross SE; Lam N; Coulson R; Yang J; Zaratzian A; Da Silva AM; Tayao M; Chin IL; Cazet A; Kansara M; Segara D; Parker A; Hoy AJ; Harvey RP; Bogdanovic O; Timpson P; Croucher DR; Lim E; Swarbrick A; Holst J; Turner N; Choi YS; Kabakova IV; Philp A; Cox TR, 2024, 'Tumor Biomechanics Alters Metastatic Dissemination of Triple Negative Breast Cancer via Rewiring Fatty Acid Metabolism', Advanced Science, 11,
    Journal articles | 2024
    Guarducci C; Nardone A; Russo D; Nagy Z; Heraud C; Grinshpun A; Zhang Q; Freelander A; Leventhal MJ; Feit A; Feit GC; Feiglin A; Liu W; Hermida-Prado F; Kesten N; Ma W; De Angelis C; Morlando A; O'Donnell M; Naumenko S; Huang S; Nguyen QD; Huang Y; Malorni L; Bergholz JS; Zhao JJ; Fraenkel E; Lim E; Schiff R; Shapiro GI; Jeselsohn R, 2024, 'Selective CDK7 Inhibition Suppresses Cell Cycle Progression and MYC Signaling While Enhancing Apoptosis in Therapy-resistant Estrogen Receptor- positive Breast Cancer', Clinical Cancer Research, 30, pp. 1889 - 1905,
    Journal articles | 2024
    Jhaveri KL; Bellet M; Turner NC; Loi S; Bardia A; Boni V; Sohn J; Neilan TG; Villanueva-Vázquez R; Kabos P; García-Estévez L; López-Miranda E; Pérez-Fidalgo JA; Pérez-García JM; Yu J; Fredrickson J; Moore HM; Chang CW; Bond JW; Eng-Wong J; Gates MR; Lim E, 2024, 'Phase Ia/b Study of Giredestrant ± Palbociclib and ± Luteinizing Hormone-Releasing Hormone Agonists in Estrogen Receptor-Positive, HER2-Negative, Locally Advanced/Metastatic Breast Cancer', Clinical Cancer Research, 30, pp. 754 - 766,
    Journal articles | 2024
    Jhaveri KL; Lim E; Jeselsohn R; Ma CX; Hamilton EP; Osborne C; Bhave M; Kaufman PA; Beck JT; Manso Sanchez L; Parajuli R; Wang H-C; Tao JJ; Im S-A; Harnden K; Yonemori K; Dhakal A; Neven P; Aftimos P; Yves-Pierga J; Lu Y-S; Larson T; Jerez Y; Sideras K; Sohn J; Kim S-B; Saura C; Bardia A; Sammons SL; Bacchion F; Li Y; Yuen E; Estrem ST; Rodrik-Outmezguine V; Nguyen B; Ismail-Khan R; Smyth L; Beeram M, 2024, 'Imlunestrant, an Oral Selective Estrogen Receptor Degrader, as Monotherapy and in Combination With Targeted Therapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Phase Ia/Ib EMBER Study.', J Clin Oncol, pp. JCO2302733,
    Journal articles | 2024
    Martín M; Lim E; Chavez-MacGregor M; Bardia A; Wu J; Zhang Q; Nowecki Z; Cruz FM; Safin R; Kim SB; Schem C; Montero AJ; Khan S; Bandyopadhyay R; Moore HM; Shivhare M; Patre M; Martinalbo J; Roncoroni L; Pérez-Moreno PD; Sohn J, 2024, 'Giredestrant for Estrogen Receptor–Positive, HER2-Negative, Previously Treated Advanced Breast Cancer: Results From the Randomized, Phase II acelERA Breast Cancer Study', Journal of Clinical Oncology, 42, pp. 2149 - 2160,
    Journal articles | 2024
    Park KH; Loibl S; Sohn J; Park YH; Jiang Z; Tadjoedin H; Nag S; Saji S; Md. Yusof M; Villegas EMB; Lim EH; Lu YS; Ithimakin S; Tseng LM; Dejthevaporn T; Chen TWW; Lee SC; Galvez C; Malwinder S; Kogawa T; Bajpai J; Brahma B; Wang S; Curigliano G; Yoshino T; Kim SB; Pentheroudakis G; Im SA; Andre F; Ahn JB; Harbeck N, 2024, 'Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with early breast cancer', ESMO Open, 9,
    Journal articles | 2024
    Peters TJ; Meyer B; Ryan L; Achinger-Kawecka J; Song J; Campbell EM; Qu W; Nair S; Loi-Luu P; Stricker P; Lim E; Stirzaker C; Clark SJ; Pidsley R, 2024, 'Characterisation and reproducibility of the HumanMethylationEPIC v2.0 BeadChip for DNA methylation profiling', BMC Genomics, 25,
    Journal articles | 2023
    André F; Hee Park Y; Kim SB; Takano T; Im SA; Borges G; Lima JP; Aksoy S; Gavila Gregori J; De Laurentiis M; Bianchini G; Roylance R; Miyoshi Y; Armstrong A; Sinha R; Ruiz Borrego M; Lim E; Ettl J; Yerushalmi R; Zagouri F; Duhoux FP; Fehm T; Gambhire D; Cathcart J; Wu C; Chu C; Egorov A; Krop I, 2023, 'Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial', The Lancet, 401, pp. 1773 - 1785,
    Journal articles | 2023
    Chen J; Wu S; Ruan T; Slapetova I; Millar E; Lim E; Swarbrick A, 2023, 'Abstract PD9-01: Stromal mediators of lymphocyte exclusion and dysfunction in triple negative breast cancer', Cancer Research, 83,
    Journal articles | 2023
    Chiu JWY; Lee SC; Ho JCM; Park YH; Chao TC; Kim SB; Lim E; Lin CH; Loi S; Low SY; Teo LLS; Yeo W; Dent R, 2023, 'Clinical Guidance on the Monitoring and Management of Trastuzumab Deruxtecan (T-DXd)-Related Adverse Events: Insights from an Asia-Pacific Multidisciplinary Panel', Drug Safety,
    Journal articles | 2023
    Chowdary P; Hastie R; Lino T; Middleton A; Capes G; Humphries A; Abed-Ali A; Anderson M; Mol BWJ; Horne A; Lim E; Andrew P; Brownfoot F; Tong S, 2023, 'Oral vinorelbine to treat women with ectopic pregnancy: a phase 1 clinical safety and tolerability study', Fertility and Sterility, 120, pp. 695 - 696,
    Journal articles | 2023
    Collier A; Chavez Mac Gregor M; Hilz S; Bardia A; Sohn J; Martin M; Lim E; Martinalbo J; Pérez-Moreno PD; Moore HM, 2023, 'Exploratory biomarker analysis of acelERA breast cancer (BC): Phase II study of giredestrant vs. physician’s choice of endocrine therapy (PCET) for previously treated, estrogen receptor-positive, HER2-negative advanced BC (ER+, HER2– aBC).', Journal of Clinical Oncology, 41, pp. 1069 - 1069,
    Journal articles | 2023
    Conway JRW; Warren SC; Lee YK; McCulloch AT; Magenau A; Lee V; Metcalf XL; Stoehr J; Haigh K; Abdulkhalek L; Guaman CS; Reed DA; Murphy KJ; Pereira BA; Mélénec P; Chambers C; Latham SL; Lenthall H; Deenick EK; Ma Y; Phan T; Lim E; Joshua AM; Walters S; Grey ST; Shi YC; Zhang L; Herzog H; Croucher DR; Philp A; Scheele CLGJ; Herrmann D; Sansom OJ; Morton JP; Papa A; Haigh JJ; Nobis M; Timpson P, 2023, 'Monitoring AKT activity and targeting in live tissue and disease contexts using a real-time Akt-FRET biosensor mouse', Science Advances, 9, pp. eadf9063,
    Journal articles | 2023
    Downton T; Karlsen E; Cuff K; Walpole E; Simpson F; Lim E, 2023, 'Abstract OT2-10-05: HER2Pro: A Phase 1b dose de-escalation study of high dose prochlorperazine added to paclitaxel, trastuzumab and pertuzumab in patients with previously untreated HER2-positive metastatic breast cancer', Cancer Research, 83,
    Journal articles | 2023
    Downton T; Segara D; Ong A; Bingham J; Carson E-K; Chen J; Middleton K; Lindeman G; Parker A; Lim E, 2023, 'Abstract OT2-01-10: WinPro: A window of opportunity study of endocrine therapy with and without prometrium in postmenopausal women with early-stage hormone receptor-positive breast cancer', Cancer Research, 83,
    Journal articles | 2023
    Freelander A; laven-Law G; Eshraghi L; Geetha N; Somerville P; Pickering M; Alexandrou S; Caldon CE; Tilley WD; Hickey TE; Lim E, 2023, 'Abstract P4-08-16: Selective Androgen Receptor Modulators in combination with CDK4/6 inhibitors demonstrate anti-cancer activity in preclinical treatment resistant ER+AR+ breast cancer models', Cancer Research, 83,
    Journal articles | 2023
    Hurwitz J; Haggstrom LR; Lim E, 2023, 'Antibody–Drug Conjugates: Ushering in a New Era of Cancer Therapy', Pharmaceutics, 15,
    Journal articles | 2023
    Jhaveri K; Wang H-C; Ma C; Lim E; Tao JJ; Manso L; Pierga J-Y; Parajuli R; Gilarranz YJ; Lu Y-S; Beeram M; Larson T; Dhakal A; Ismail-Khan R; Karacsonyi C; Cao S; Osborne C; Estrem ST; Nguyen B; Li Y; Yuen E, 2023, 'Abstract PD13-12: PD13-12 Imlunestrant, an oral selective estrogen receptor degrader, in combination with abemaciclib with or without an aromatase inhibitor, in estrogen receptor-positive advanced breast cancer: Results from the phase 1a/b EMBER study', Cancer Research, 83,
    Journal articles | 2023
    Karimi L; Alves CL; Terp MG; Tuttolomondo M; Portman N; Ehmsen S; Johansen LE; Bak M; Lim E; Ditzel HJ, 2023, 'Triple combination targeting PI3K, ER, and CDK4/6 inhibits growth of ER-positive breast cancer resistant to fulvestrant and CDK4/6 or PI3K inhibitor', Cancer Communications, 43, pp. 720 - 725,
    Journal articles | 2023
    Krop I; Park YH; Kim S-B; Borges G; Aksoy S; Gregori JG; Roylance R; Lim E; Yerushalmi R; Zagouri F; Duhoux FP; Fehm T; Takano T; Egorov A; Wu I; Cathcart J; Chu C; Andre F, 2023, 'Abstract GS2-01: GS2-01 Trastuzumab deruxtecan vs physician’s choice in patients with HER2+ unresectable and/or metastatic breast cancer previously treated with trastuzumab emtansine: primary results of the randomized, phase 3 study DESTINY-Breast02', Cancer Research, 83,
    Journal articles | 2023
    Lim E; Chavez M; Bardia A; Sohn JH; Moore HM; Shivhare M; Martinalbo J; Roncoroni L; Perez-Moreno PD; Martín M, 2023, 'Abstract PD13-04: PD13-04 Exploratory subgroup and biomarker analyses of acelERA Breast Cancer: Phase II study of giredestrant (GDC-9545) vs physician’s choice of endocrine therapy for previously treated, estrogen receptor+, HER2– advanced breast cancer', Cancer Research, 83,
    Journal articles | 2023
    Lim E; Hamilton E; Palmieri C; Arkenau H-T; Brook S; Fisher G; Mazur A, 2023, 'Abstract OT1-02-02: A phase 1/2 study to evaluate the safety and efficacy of EP0062, an oral Selective Androgen Receptor Modulator (SARM), for the treatment of AR+/HER2-/ER+ advanced breast cancer', Cancer Research, 83,
    Journal articles | 2023
    Zhou FH; Downton T; Freelander A; Hurwitz J; Caldon CE; Lim E, 2023, 'CDK4/6 inhibitor resistance in estrogen receptor positive breast cancer, a 2023 perspective', Frontiers in Cell and Developmental Biology, 11,
    Journal articles | 2022
    Berthelet J; Foroutan M; Bhuva DD; Whitfield HJ; El-Saafin F; Cursons J; Serrano A; Merdas M; Lim E; Charafe-Jauffret E; Ginestier C; Ernst M; Hollande F; Anderson RL; Pal B; Yeo B; Davis MJ; Merino D, 2022, 'Computational Screening of Anti-Cancer Drugs Identifies a New BRCA Independent Gene Expression Signature to Predict Breast Cancer Sensitivity to Cisplatin', Cancers, 14,
    Journal articles | 2022
    Brown LJ; Achinger-Kawecka J; Portman N; Clark S; Stirzaker C; Lim E, 2022, 'Epigenetic Therapies and Biomarkers in Breast Cancer', Cancers, 14, pp. 474 - 474,
    Journal articles | 2022
    Dinh P; Graham JD; Elder EN; Kabir M; Doan TB; French J; Meybodi F; Hui R; Wilcken NR; Harnett PR; Hsu J; Stuart KE; Wang T; Ahern V; Brennan M; Fox SB; Dear RF; Lim E; White M; Mann GB; Pathmanathan N, 2022, 'Impact of the EndoPredict genomic assay on treatment decisions for oestrogen receptor-positive early breast cancer patients: benefits of physician selective testing', Breast Cancer Research and Treatment, 191, pp. 501 - 511,
    Journal articles | 2022
    Downton T; Zhou F; Segara D; Jeselsohn R; Lim E, 2022, 'Oral Selective Estrogen Receptor Degraders (SERDs) in Breast Cancer: Advances, Challenges, and Current Status', Drug Design, Development and Therapy, 16, pp. 2933 - 2948,
    Journal articles | 2022
    Haggstrom LR; Vardy JL; Carson EK; Segara D; Lim E; Kiely BE, 2022, 'Effects of Endocrine Therapy on Cognitive Function in Patients with Breast Cancer: A Comprehensive Review', Cancers, 14,
    Journal articles | 2022
    Lim E; Boyle F; Okera M; Loi S; Goksu SS; van Hal G; Chapman SC; Gable JC; Chen Y; Price GL; Hossain AM; Gainford MC; Ezquerra MB, 2022, 'An open label, randomized phase 2 trial assessing the impact of food on the tolerability of abemaciclib in patients with advanced breast cancer', Breast Cancer Research and Treatment, 195, pp. 275 - 287,
    Journal articles | 2022
    Martin Jimenez M; Lim E; Chavez Mac Gregor M; Bardia A; Wu J; Zhang Q; Nowecki Z; Cruz F; Safin R; Kim S-B; Schem C; Montero A; Khan S; Bandyopadhyay R; Shivhare M; Patre M; Martinalbo J; Roncoroni L; Pérez-Moreno PD; Sohn J, 2022, '211MO Giredestrant (GDC-9545) vs physician choice of endocrine monotherapy (PCET) in patients (pts) with ER+, HER2– locally advanced/metastatic breast cancer (LA/mBC): Primary analysis of the phase II, randomised, open-label acelERA BC study', Annals of Oncology, 33, pp. S633 - S634,
    Journal articles | 2022
    Morrow RJ; Allam AH; Yeo B; Deb S; Murone C; Lim E; Johnstone CN; Ernst M, 2022, 'Paracrine IL-6 Signaling Confers Proliferation between Heterogeneous Inflammatory Breast Cancer Sub-Clones', Cancers, 14, pp. 2292 - 2292,
    Journal articles | 2022
    Nguyen A; Fullard K; Sheehan-Dare G; Tang R; Chan L; Ho B; Dear R; Keane J; Hickey A; Nandurkar R; Chen J; Chen A; Lim E; Emmett L, 2022, 'Diagnostic value of 68Ga-DOTATATE PET-CT imaging for staging of ER+/PR+ HER2- breast cancer patients with metastatic disease: Comparison with conventional imaging with bone scan, diagnostic CT and 18F-FDG PET-CT in a prospective pilot trial', Journal of Medical Imaging and Radiation Oncology, 66, pp. 731 - 737,
    Journal articles | 2022
    Papanicolaou M; Parker AL; Yam M; Filipe EC; Wu SZ; Chitty JL; Wyllie K; Tran E; Mok E; Nadalini A; Skhinas JN; Lucas MC; Herrmann D; Nobis M; Pereira BA; Law AMK; Castillo L; Murphy KJ; Zaratzian A; Hastings JF; Croucher DR; Lim E; Oliver BG; Mora FV; Parker BL; Gallego-Ortega D; Swarbrick A; O’Toole S; Timpson P; Cox TR, 2022, 'Temporal profiling of the breast tumour microenvironment reveals collagen XII as a driver of metastasis', Nature Communications, 13,
    Journal articles | 2022
    Portman N; Lim E, 2022, 'A new sophistication for breast cancer PDXs', Nature Cancer, 3, pp. 138 - 140,
    Journal articles | 2022
    Wong K; Sheehan-Dare G; Nguyen A; Ho B; Liu V; Lee J; Brown L; Dear R; Chan L; Sharma S; Malaroda A; Smith I; Lim E; Emmett L, 2022, '64Cu-SAR-Bombesin PET-CT Imaging in the Staging of Estrogen/Progesterone Receptor Positive, HER2 Negative Metastatic Breast Cancer Patients: Safety, Dosimetry and Feasibility in a Phase I Trial', Pharmaceuticals, 15,
    Journal articles | 2022
    Wong V; de Boer R; Baron-Hay S; Blum R; Boyle F; Chua S; Clarke K; Cuff K; Green M; Lim E; Mok K; Nott L; Nottage M; Tafreshi A; Tsoi D; Uccellini A; Hong W; Gibbs P; Lok SW, 2022, 'Real-World Outcomes of Ribociclib and Aromatase Inhibitor Use in First Line Hormone Receptor Positive, HER2-Negative Metastatic Breast Cancer', Clinical Breast Cancer, 22, pp. 792 - 800,
    Journal articles | 2021
    Achinger-Kawecka J; Stirzaker C; Portman N; Campbell E; Chia K-M; Du Q; Laven-Law G; Nair S; Yong A; Wilkinson A; Clifton S; Milioli H; Alexandrou S; Caldon E; Song J; Khoury A; Meyer B; Gee JMW; Schmitt A; Wong E; Hickey T; Lim E; Clark S, 2021, 'Epigenetic therapy targets the 3D epigenome in endocrine-resistant breast cancer', ,
    Journal articles | 2021
    Alves CL; Ehmsen S; Terp MG; Portman N; Tuttolomondo M; Gammelgaard OL; Hundebøl MF; Kaminska K; Johansen LE; Bak M; Honeth G; Bosch A; Lim E; Ditzel HJ, 2021, 'Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer', Nature Communications, 12,
    Journal articles | 2021
    Alves CL; Ehmsen S; Terp MG; Portman N; Tuttolomondo M; Gammelgaard OL; Hundebøl MF; Kaminska K; Johansen LE; Bak M; Honeth G; Bosch A; Lim E; Ditzel HJ, 2021, 'Publisher Correction: Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer (Nature Communications, (2021), 12, 1, (5112), 10.1038/s41467-021-25422-9)', Nature Communications, 12,
    Journal articles | 2021
    Ardolino L; Lau B; Wilson I; Chen J; Borella L; Stone E; Lim E, 2021, 'Case Report: Paclitaxel-Induced Pneumonitis in Early Breast Cancer: A Single Institution Experience and Review', Frontiers in Oncology, 11,
    Journal articles | 2021
    Aziz D; Portman N; Fernandez KJ; Lee C; Alexandrou S; Llop-Guevara A; Phan Z; Yong A; Wilkinson A; Sergio CM; Ferraro D; Etemadmoghadam D; Bowtell DD; Serra V; Waring P; Lim E; Caldon CE, 2021, 'Synergistic targeting of BRCA1 mutated breast cancers with PARP and CDK2 inhibition', npj Breast Cancer, 7,
    Journal articles | 2021
    Brown LJ; Meredith T; Yu J; Patel A; Neal B; Arnott C; Lim E; Yu J, 2021, 'Heart failure therapies for the prevention of her2-monoclonal antibody-mediated cardiotoxicity: A systematic review and meta-analysis of randomized trials', Cancers, 13, pp. 5527,
    Journal articles | 2021
    Chen J; Colosimo M; Lim E, 2021, 'The management of HER2-positive early breast cancer: Current and future therapies', Asia-Pacific Journal of Clinical Oncology, 17, pp. 3 - 12,
    Journal articles | 2021
    Chew NJ; Lim Kam Sian TCC; Nguyen EV; Shin SY; Yang J; Hui MN; Deng N; McLean CA; Welm AL; Lim E; Gregory P; Nottle T; Lang T; Vereker M; Richardson G; Kerr G; Micati D; Jardé T; Abud HE; Lee RS; Swarbrick A; Daly RJ, 2021, 'Evaluation of FGFR targeting in breast cancer through interrogation of patient-derived models', Breast Cancer Research, 23,
    Journal articles | 2021
    Du Q; Smith GC; Luu PL; Ferguson JM; Armstrong NJ; Caldon CE; Campbell EM; Nair SS; Zotenko E; Gould CM; Buckley M; Chia KM; Portman N; Lim E; Kaczorowski D; Chan CL; Barton K; Deveson IW; Smith MA; Powell JE; Skvortsova K; Stirzaker C; Achinger-Kawecka J; Clark SJ, 2021, 'DNA methylation is required to maintain both DNA replication timing precision and 3D genome organization integrity', Cell Reports, 36,
    Journal articles | 2021
    Freelander A; Brown LJ; Parker A; Segara D; Portman N; Lau B; Lim E, 2021, 'Molecular biomarkers for contemporary therapies in hormone receptor‐positive breast cancer', Genes, 12, pp. 1 - 24,
    Journal articles | 2021
    Harbeck N; Rastogi P; Martin M; Tolaney SM; Shao ZM; Fasching PA; Huang CS; Jaliffe GG; Tryakin A; Goetz MP; Rugo HS; Senkus E; Testa L; Andersson M; Tamura K; Del Mastro L; Steger GG; Kreipe H; Hegg R; Sohn J; Guarneri V; Cortés J; Hamilton E; André V; Wei R; Barriga S; Sherwood S; Forrester T; Munoz M; Shahir A; San Antonio B; Nabinger SC; Toi M; Johnston SRD; O'Shaughnessy J; Jimenez MM; Johnston S; Boyle F; Neven P; Jiang Z; Campone M; Huober J; Shimizu C; Cicin I; Wardley A; Abuin GG; Zarba J; Lim E; Sant P; Liao N; Christiansen B; Eigeliene N; Martin-Babau J; Ettl J; Mavroudis D; Chiu J; Boer K; Nagarkar R; Paluch-Shimon S; Moscetti L; Sagara Y; Kim SB; Maciel MM; Tjan-Heijnen V; Broom R; Lacko A; Schenker M; Volkov N; Sim Yap Y; Coccia-Portugal M; Ángel García Sáenz J; Andersson A; Chao TY; Gokmen E; Harputluoglu H; Berzoy O; Patt D; McArthur H; Chew H; Chalasani P; Kaufman P; Tedesco K; Graff SL, 2021, 'Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study', Annals of Oncology, 32, pp. 1571 - 1581,
    Journal articles | 2021
    Hickey TE; Selth LA; Chia KM; Laven-Law G; Milioli HH; Roden D; Jindal S; Hui M; Finlay-Schultz J; Ebrahimie E; Birrell SN; Stelloo S; Iggo R; Alexandrou S; Caldon CE; Abdel-Fatah TM; Ellis IO; Zwart W; Palmieri C; Sartorius CA; Swarbrick A; Lim E; Carroll JS; Tilley WD, 2021, 'The androgen receptor is a tumor suppressor in estrogen receptor–positive breast cancer', Nature Medicine, 27, pp. 310 - 320,
    Journal articles | 2021
    Hui R; de Boer R; Lim E; Yeo B; Lynch J, 2021, 'CDK4/6 inhibitor plus endocrine therapy for hormone receptor-positive, HER2-negative metastatic breast cancer: The new standard of care', Asia-Pacific Journal of Clinical Oncology, 17, pp. 3 - 14,
    Journal articles | 2021
    Jhaveri KL; Boni V; Sohn J; Villanueva-Vasquez R; Bardia A; Schmid P; Lim E; Patel JM; Alejandro Perez-Fidalgo J; Loi S; Im S-A; Kshirsagar S; Gates MR; Bond J; Eng-Wong J; Chang C-W; Turner NC; Lopez Miranda E; Garcia-Estevez L; Bellet M, 2021, 'Safety and activity of single-agent giredestrant (GDC-9545) from a phase Ia/b study in patients (pts) with estrogen receptor-positive (ER+), HER2-negative locally advanced/metastatic breast cancer (LA/mBC).', JOURNAL OF CLINICAL ONCOLOGY, 39,
    Journal articles | 2021
    Jhaveri KL; Lim E; Hamilton EP; Saura C; Meniawy T; Jeselsohn R; Beck JT; Kaufman PA; Sammons S; Banda K; Okera M; Yonemori K; Harnden KK; Kim S-B; Sohn J; Ma CX; Aftimos PG; Wang XA; Young SRL; Beeram M, 2021, 'A first-in-human phase 1a/b trial of LY3484356, an oral selective estrogen receptor (ER) degrader (SERD) in ER plus advanced breast cancer (aBC) and endometrial endometrioid cancer (EEC): Results from the EMBER study.', JOURNAL OF CLINICAL ONCOLOGY, 39,
    Journal articles | 2021
    Kumar S; Freelander A; Lim E, 2021, 'Type 1 nuclear receptor activity in breast cancer: Translating preclinical insights to the clinic', Cancers, 13, pp. 4972 - 4972,
    Journal articles | 2021
    Martin M; Lim E; Mac Gregor MC; Shivhare M; Ross G; Patre M; Roncoroni L; Louka M; Sohn J, 2021, 'acelERA Breast Cancer (BC): Phase II study evaluating efficacy and safety of giredestrant (GDC-9545) versus physician's choice of endocrine monotherapy in patients (pts) with estrogen receptor-positive, HER2-negative (ER+/HER2-) locally advanced or metastatic breast cancer (LA/mBC).', JOURNAL OF CLINICAL ONCOLOGY, 39,
    Journal articles | 2021
    Palmieri C; Linden HM; Birrell S; Lim E; Schwartzberg LS; Rugo HS; Cobb PW; Jain K; Vogel CL; O'Shaughnessy J; Johnston SRD; Getzenberg RH; Barnette KG; Steiner MS; Brufsky A; Overmoyer B, 2021, 'Efficacy of enobosarm, a selective androgen receptor (AR) targeting agent, correlates with the degree of AR positivity in advanced AR+/estrogen receptor (ER)+ breast cancer in an international phase 2 clinical study.', Journal of Clinical Oncology, 39, pp. 1020 - 1020,
    Journal articles | 2021
    Portman N; Chen J; Lim E, 2021, 'MDM2 as a Rational Target for Intervention in CDK4/6 Inhibitor Resistant, Hormone Receptor Positive Breast Cancer', Frontiers in Oncology, 11,
    Journal articles | 2021
    Wong V; de Boer R; Baron-Hay SE; Blum RH; Forster BC; Chua SLL; Cuff K; Green M; Lim E; Mok K; Nott LM; Nottage MK; Tafreshi A; Tsoi DTF; Yeo B; Gibbs P; Lok SW, 2021, 'Australian real-world outcomes of ribociclib and aromatase inhibitor in hormone receptor (HR) positive, HER2 negative metastatic breast cancer (MBC): Results from Kisqali Access Registry for Metastatic breast cancer in Australia (KARMA) collected alongside a medicine access program.', Journal of Clinical Oncology, 39, pp. e13018 - e13018,
    Journal articles | 2021
    Wu SZ; Al-Eryani G; Roden DL; Junankar S; Harvey K; Andersson A; Thennavan A; Wang C; Torpy JR; Bartonicek N; Wang T; Larsson L; Kaczorowski D; Weisenfeld NI; Uytingco CR; Chew JG; Bent ZW; Chan CL; Gnanasambandapillai V; Dutertre CA; Gluch L; Hui MN; Beith J; Parker A; Robbins E; Segara D; Cooper C; Mak C; Chan B; Warrier S; Ginhoux F; Millar E; Powell JE; Williams SR; Liu XS; O’Toole S; Lim E; Lundeberg J; Perou CM; Swarbrick A, 2021, 'A single-cell and spatially resolved atlas of human breast cancers', Nature Genetics, 53, pp. 1334 - 1347,
    Journal articles | 2021
    Wu SZ; Roden DL; Al-Eryani G; Bartonicek N; Harvey K; Cazet AS; Chan CL; Junankar S; Hui MN; Millar EA; Beretov J; Horvath L; Joshua AM; Stricker P; Wilmott JS; Quek C; Long GV; Scolyer RA; Yeung BZ; Segara D; Mak C; Warrier S; Powell JE; O’Toole S; Lim E; Swarbrick A, 2021, 'Cryopreservation of human cancers conserves tumour heterogeneity for single-cell multi-omics analysis', Genome Medicine, 13,
    Journal articles | 2021
    2021, 'Evaluation of pharmacodynamic (PD) and biologic activity in a preoperative window-of-opportunity (WOO) study of giredestrant (GDC-9545) in postmenopausal patients (pts) with estrogen receptor-positive, HER2-negative (ER+/HER2-) operable breast cancer (BC).', JOURNAL OF CLINICAL ONCOLOGY, 39,
    Journal articles | 2020
    Baker LA; Baker LA; Holliday H; Roden D; Krisp C; Wu SZ; Junankar S; Junankar S; Serandour AA; Mohammed H; Nair R; Sankaranarayanan G; Law AMK; Law AMK; McFarland A; Simpson PT; Lakhani S; Dodson E; Selinger C; Anderson L; Anderson L; Samimi G; Hacker NF; Lim E; Ormandy CJ; Naylor MJ; Simpson K; Nikolic I; O'Toole S; Kaplan W; Cowley MJ; Carroll JS; Molloy M; Swarbrick A, 2020, 'Proteogenomic analysis of Inhibitor of Differentiation 4 (ID4) in basal-like breast cancer', Breast Cancer Research, 22, pp. 63,
    Journal articles | 2020
    Chen J; Easwaralingam N; Warrier S; Ong A; Carson EK; Mak C; Snook K; Middleton K; Parker A; Palmieri C; Spillane A; Mann GB; Lim E; Segara D, 2020, 'Window of opportunity treatment in breast cancer', ANZ Journal of Surgery, 90, pp. 34 - 40,
    Journal articles | 2020
    Chia KM; Freelander A; Kumar S; Parker A; Segara D; Portman N; Lim E, 2020, 'Estrogen receptor positive breast cancer patient–derived xenograft models in translational research', Current Opinion in Endocrine and Metabolic Research, 15, pp. 31 - 36,
    Journal articles | 2020
    Light M; McFarlane T; Ives A; Shah B; Lim E; Grossmann M; Zajac JD; Cheung AS, 2020, 'Testosterone therapy considerations in oestrogen, progesterone and androgen receptor–positive breast cancer in a transgender man', Clinical Endocrinology, 93, pp. 355 - 357,
    Journal articles | 2020
    Lim E; Jhaveri KL; Perez-Fidalgo JA; Bellet M; Boni V; Perez Garcia JM; Estevez L; Bardia A; Turner NC; Villanueva R; Lopez-Tarruella Cobo S; Im S-A; Kim S-B; Gates MR; Monemi S; Chen Y-C; Moore H; Loi S; Sohn J, 2020, 'A phase Ib study to evaluate the oral selective estrogen receptor degrader GDC-9545 alone or combined with palbociclib in metastatic ER-positive HER2-negative breast cancer.', Journal of Clinical Oncology, 38, pp. 1023 - 1023,
    Journal articles | 2020
    Milioli HH; Alexandrou S; Lim E; Caldon CE, 2020, 'Cyclin E1 and cyclin E2 in ER+ breast cancer: Prospects as biomarkers and therapeutic targets', Endocrine-Related Cancer, 27, pp. R93 - R112,
    Journal articles | 2020
    Portman N; Milioli HH; Alexandrou S; Coulson R; Yong A; Fernandez KJ; Chia KM; Halilovic E; Segara D; Parker A; Haupt S; Haupt Y; Tilley WD; Swarbrick A; Caldon CE; Lim E, 2020, 'MDM2 inhibition in combination with endocrine therapy and CDK4/6 inhibition for the treatment of ER-positive breast cancer', Breast Cancer Research, 22, pp. 87,
    Journal articles | 2020
    Portman N; Milioli HH; Alexandrou S; Coulson R; Yong A; Fernandez KJ; Chia KM; Segara D; Parker A; Haupt S; Haupt Y; Tilley WD; Swarbrick A; Caldon CE; Lim E, 2020, 'MDM2 Inhibition in Combination with Endocrine Therapy and CDK4/6 Inhibition for the Treatment of ER-Positive Breast Cancer', ,
    Journal articles | 2020
    Tadesse S; Anshabo AT; Portman N; Lim E; Tilley W; Caldon CE; Wang S, 2020, 'Targeting CDK2 in cancer: challenges and opportunities for therapy', Drug Discovery Today, 25, pp. 406 - 413,
    Journal articles | 2020
    Wu S; Roden D; Al-Eryani G; Bartonicek N; Harvey K; Cazet A; Chan C-L; Junankar S; Hui M; Millar E; Beretov J; Horvath L; Joshua A; Stricker P; Wilmott J; Quek C; Long G; Scolyer R; Yeung B; Segara D; Mak C; Warrier S; Powell J; O'Toole S; Lim E; Swarbrick A, 2020, 'Cryopreservation of human cancers conserves tumour heterogeneity for single-cell multi-omics analysis', bioRxiv,
    Journal articles | 2020
    Wu S; Roden D; Wang C; Holliday H; Harvey K; Cazet A; Murphy K; Pereira B; Al-Eryani G; Bartonicek N; Hou R; Torpy J; Junankar S; Chan C-L; Lam E; Hui M; Gluch L; Beith J; Parker A; Robbins E; Segara D; Mak C; Cooper C; Warrier S; Forrest A; Powell J; O’Toole S; Cox T; Timpson P; Lim E; Liu S; Swarbrick A, 2020, 'Single-cell analysis reveals diverse stromal subsets associated with immune evasion in triple-negative breast cancer', bioRxiv,
    Journal articles | 2020
    Wu SZ; Roden DL; Wang C; Holliday H; Harvey K; Cazet AS; Murphy KJ; Pereira B; Al-Eryani G; Bartonicek N; Hou R; Torpy JR; Junankar S; Chan CL; Lam CE; Hui MN; Gluch L; Beith J; Parker A; Robbins E; Segara D; Mak C; Cooper C; Warrier S; Forrest A; Powell J; O'Toole S; Cox TR; Timpson P; Lim E; Liu XS; Swarbrick A, 2020, 'Stromal cell diversity associated with immune evasion in human triple-negative breast cancer', EMBO Journal, 39, pp. e104063,
    Journal articles | 2020
    Yang Y; Cooper C; Robbins E; Swarbrick A; Harvey K; Lim E; Mak C; Carmalt H; Warrier S; Chan B; Beith J; Hui M; Gluch L; O’Toole S; Cooper W, 2020, '9. Factors influencing the success rate of patient derived xenograft formation from breast cancer specimens', Pathology, 52, pp. S136 - S136,
    Journal articles | 2020
    de Boer R; Hui R; Lim E; Yeo B; Zdenkowski N, 2020, 'Optimizing care for younger women with hormone receptor-positive, HER2-negative metastatic breast cancer', Asia-Pacific Journal of Clinical Oncology, 16, pp. 3 - 14,
    Journal articles | 2019
    Alexandrou S; George SM; Ormandy CJ; Lim E; Oakes SR; Elizabeth Caldon C, 2019, 'The proliferative and apoptotic landscape of basal-like breast cancer', International Journal of Molecular Sciences, 20,
    Journal articles | 2019
    Chi D; Singhal H; Li L; Xiao T; Liu W; Pun M; Jeselsohn R; He H; Lim E; Vadhi R; Rao P; Long H; Garber J; Brown M, 2019, 'Estrogen receptor signaling is reprogrammed during breast tumorigenesis', Proceedings of the National Academy of Sciences of the United States of America, 166, pp. 11437 - 11443,
    Journal articles | 2019
    Chia KM; Milioli H; Portman N; Laven-Law G; Coulson R; Yong A; Segara D; Parker A; Caldon CE; Deng N; Swarbrick A; Tilley WD; Hickey TE; Lim E, 2019, 'Non-canonical AR activity facilitates endocrine resistance in breast cancer', Endocrine-Related Cancer, 26, pp. 251 - 264,
    Journal articles | 2019
    Field AS; Raymond WA; Rickard M; Arnold L; Brachtel EF; Chaiwun B; Chen L; Di Bonito L; Kurtycz DFI; Lee AHS; Lim E; Ljung BM; Michelow P; Osamura RY; Pinamonti M; Sauer T; Segara D; Tse G; Vielh P; Chong PY; Schmitt F, 2019, 'The international academy of cytology yokohama system for reporting breast fine-needle aspiration biopsy cytopathology', Acta Cytologica, 63, pp. 257 - 273,
    Journal articles | 2019
    Field AS; Schmitt F; Raymond F, 2019, 'The IAC Yokohama system for reporting breast FNAB cytology', Acta Cytologica, 63, pp. 257 - 273,
    Journal articles | 2019
    Grossmann M; Ramchand SK; Milat F; Vincent A; Lim E; Kotowicz MA; Hicks J; Teede HJ, 2019, 'Assessment and management of bone health in women with oestrogen receptor-positive breast cancer receiving endocrine therapy: position statement summary', Medical Journal of Australia, 211, pp. 224 - 229,
    Journal articles | 2019
    Juan BPS; Zadeh S; Ganju V; Vargas C; O'Toole S; Lim E; Davis M; Chaffer C, 2019, 'Unravelling the role of cell plasticity in BrCa development and metastasis', Oncology Abstracts,
    Journal articles | 2019
    Kennedy SP; Han JZR; Portman N; Nobis M; Hastings JF; Murphy KJ; Latham SL; Cadell AL; Miladinovic D; Marriott GR; O'Donnell YEI; Shearer RF; Williams JT; Munoz AG; Cox TR; Watkins DN; Saunders DN; Timpson P; Lim E; Kolch W; Croucher DR, 2019, 'Targeting promiscuous heterodimerization overcomes innate resistance to ERBB2 dimerization inhibitors in breast cancer', Breast Cancer Research, 21,
    Journal articles | 2019
    Lee KWC; Lord S; Finn RS; Lim E; Martin A; Loi S; Lynch J; Friedlander M; Lee CK, 2019, 'The impact of ethnicity on efficacy and toxicity of cyclin D kinase 4/6 inhibitors in advanced breast cancer: a meta-analysis', Breast Cancer Research and Treatment, 174, pp. 271 - 278,
    Journal articles | 2019
    Portman N; Alexandrou S; Carson E; Wang S; Lim E; Caldon CE, 2019, 'Overcoming CDK4/6 inhibitor resistance in ER-positive breast cancer', Endocrine-Related Cancer, 26, pp. R15 - R30,
    Journal articles | 2019
    Roden D; Wu S; Harvey K; Chan C-L; Al-Eryani G; Cazet A; Lim E; Swarbrick A, 2019, 'Single-cell transcriptomics reveals marked heterogeneity for intrinsic molecular subtype and cellular function in estrogen receptor positive breast cancer', Oncology Abstracts,
    Journal articles | 2019
    Thompson EJ; Duluc C; Barry EF; Farshid G; Simpson KJ; Gregory PA; Li X; Madden S; Owczarek CM; Wilson NJ; Vairo G; Nash AD; Ingman WV; Lindeman GJ; Lim E; Khew-Goodall Y; Lopez AF; Bonder CS, 2019, 'Expression of the interleukin-3/receptor complex by breast cancer cells promotes vascular mimicry via a PI3K-dependent mechanism and is associated with poor outcome', Oncology Abstracts,
    Journal articles | 2019
    Young AR; Duarte JDG; Coulson R; O’brien M; Deb S; Lopata A; Behren A; Mathivanan S; Lim E; Meeusen E, 2019, 'Immunoprofiling of breast cancer antigens using antibodies derived from local lymph nodes', Cancers, 11,
    Journal articles | 2018
    Boyle F; Beith J; Burslem K; de Boer R; Hui R; Lim E; McCarthy N; Redfern A; Woodward N, 2018, 'Hormone receptor positive, HER2 negative metastatic breast cancer: Impact of CDK4/6 inhibitors on the current treatment paradigm', Asia-Pacific Journal of Clinical Oncology, 14, pp. 3 - 11,
    Journal articles | 2018
    Cazet AS; Hui MN; Elsworth BL; Wu SZ; Roden D; Chan CL; Skhinas JN; Collot R; Yang J; Harvey K; Johan MZ; Cooper C; Nair R; Herrmann D; McFarland A; Deng N; Ruiz-Borrego M; Rojo F; Trigo JM; Bezares S; Caballero R; Lim E; Timpson P; O’Toole S; Watkins DN; Cox TR; Samuel MS; Martín M; Swarbrick A; O'Toole S, 2018, 'Targeting stromal remodeling and cancer stem cell plasticity overcomes chemoresistance in triple negative breast cancer', Nature Communications, 9, pp. 2897,
    Journal articles | 2018
    Galimberti V; Cole BF; Viale G; Veronesi P; Vicini E; Intra M; Mazzarol G; Massarut S; Zgajnar J; Taffurelli M; Littlejohn D; Knauer M; Tondini C; Di Leo A; Colleoni M; Regan MM; Coates AS; Gelber RD; Goldhirsch A; Boyle F; Jerusalem G; Stahel R; Aebi S; Green M; Karlsson P; Kössler I; Láng I; Hiltbrunner A; Bernhard J; Fournarakou S; Kammler R; Maibach R; Rabaglio M; Ribi K; Roschitzki H; Roux S; Ruepp B; Mahoney C; Price K; Blacher L; Scolese T; Scott K; Lippert S; Zielinski T; Mastropasqua M; Andrighetto S; Dell'Orto P; Renne G; Pruneri G; Dellapasqua S; Iorfida M; Cancello G; Montagna E; Cardillo A; Peruzzotti G; Ghisini R; Luini A; Veronesi U; Gentilini O; Zurrida S; Curigliano G; Nole F; Orecchia R; Leonardi MC; Baratella P; Chifu C; Sargenti M; Crivellari D; Morassut S; Mileto M; Piccoli E; Veronesi A; Magri MD; Buonadonna A; Candiani E; Carbone A; Perin T; Volpe R; Roncadin M; Arcicasa M; Coran F; Lagrassa M; Recalcati A; Limonta ME; Tricomi P; Fenaroli P; Candiago E; Cattaneo L; Gianatti A; Santini D; Maweja S; Delvenne P; Rorive A; Collignon J; Garbay JR; Mathieu MC; Galatius H; Hoffmann J; Schousen P, 2018, 'Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trial', The Lancet Oncology, 19, pp. 1385 - 1393,
    Journal articles | 2018
    Grossmann M; Ramchand SK; Milat F; Vincent A; Lim E; Kotowicz MA; Hicks J; Teede H, 2018, 'Assessment and management of bone health in women with oestrogen receptor-positive breast cancer receiving endocrine therapy: Position statement of the Endocrine Society of Australia, the Australian and New Zealand Bone & Mineral Society, the Australasian Menopause Society and the Clinical Oncology Society of Australia', Clinical Endocrinology, 89, pp. 280 - 296,
    Journal articles | 2018
    Hastie R; Lim E; Sluka P; Campbell L; Horne AW; Ellett L; Hannan NJ; Brownfoot F; Kaitu'u-Lino TJ; Tong S, 2018, 'Vinorelbine Potently Induces Placental Cell Death, Does Not Harm Fertility and is a Potential Treatment for Ectopic Pregnancy', EBioMedicine, 29, pp. 166 - 176,
    Journal articles | 2018
    Lim E; Beith J; Boyle F; de Boer R; Hui R; McCarthy N; Redfern A; Wade T; Woodward N, 2018, 'Emerging data and future directions for CDK4/6 inhibitor treatment of patients with hormone receptor positive HER2-non-amplified metastatic breast cancer', Asia-Pacific Journal of Clinical Oncology, 14, pp. 12 - 21,
    Journal articles | 2018
    Papachristou EK; Kishore K; Holding AN; Harvey K; Roumeliotis TI; Chilamakuri CSR; Omarjee S; Chia KM; Swarbrick A; Lim E; Markowetz F; Eldridge M; Siersbaek R; D’Santos CS; Carroll JS, 2018, 'A quantitative mass spectrometry-based approach to monitor the dynamics of endogenous chromatin-associated protein complexes', Nature Communications, 9,
    Journal articles | 2018
    Robinson DH; Churilov L; Lin NU; Lim E; Seah D, 2018, 'Attitudes of patients with metastatic cancer towards research biopsies', Asia-Pacific Journal of Clinical Oncology, 14, pp. 231 - 238,
    Journal articles | 2018
    Roswall P; Bocci M; Bartoschek M; Li H; Kristiansen G; Jansson S; Lehn S; Sjölund J; Reid S; Larsson C; Eriksson P; Anderberg C; Cortez E; Saal LH; Orsmark-Pietras C; Cordero E; Haller BK; Häkkinen J; Burvenich IJG; Lim E; Orimo A; Höglund M; Rydén L; Moch H; Scott AM; Eriksson U; Pietras K, 2018, 'Microenvironmental control of breast cancer subtype elicited through paracrine platelet-derived growth factor-CC signaling', Nature Medicine, 24, pp. 463 - 473,
    Journal articles | 2018
    Wang Y; Li YM; Baitsch L; Huang A; Xiang Y; Tong H; Lako A; Von T; Choi C; Lim E; Min J; Li L; Stegmeier F; Schlegel R; Eck MJ; Gray NS; Mitchison TJ; Zhao JJ, 2018, 'Erratum: Correction: MELK is an oncogenic kinase essential for mitotic progression in basal-like breast cancer cells (eLife (2014) 3 (e01763) PII: e36414)', eLife, 7,
    Journal articles | 2017
    Brockwell NK; Owen KL; Zanker D; Spurling A; Rautela J; Duivenvoorden HM; Baschuk N; Caramia F; Loi S; Darcy PK; Lim E; Parker BS, 2017, 'Neoadjuvant interferons: Critical for effective PD-1–based immunotherapy in TNBC', Cancer Immunology Research, 5, pp. 871 - 884,
    Journal articles | 2017
    Dreijerink KMA; Groner AC; Vos ESM; Font-Tello A; Gu L; Chi D; Reyes J; Cook J; Lim E; Lin CY; de Laat W; Rao PK; Long HW; Brown M, 2017, 'Enhancer-Mediated Oncogenic Function of the Menin Tumor Suppressor in Breast Cancer', Cell Reports, 18, pp. 2359 - 2372,
    Journal articles | 2017
    Haupt S; Vijayakumaran R; Miranda PJ; Burgess A; Lim E; Haupt Y, 2017, 'The role of MDM2 and MDM4 in breast cancer development and prevention', Journal of molecular cell biology, 9, pp. 53 - 61,
    Journal articles | 2017
    Law AMK; Lim E; Ormandy CJ; Gallego-Ortega D, 2017, 'Erratum: The innate and adaptive infiltrating immune systems as targets for breast cancer immunotherapy (Endocrine-related cancer (2017) 24 4 (R123-R144) PII: ERC160404e)', Endocrine-related cancer, 24, pp. X1,
    Journal articles | 2017
    Law AMK; Lim E; Ormandy CJ; Gallego-Ortega D, 2017, 'The innate and adaptive infiltrating immune systems as targets for breast cancer immunotherapy', Endocrine-Related Cancer, 24, pp. R123 - R144,
    Journal articles | 2017
    Lim E; Johnson SF; Geyer M; Serra V; Shapiro GI, 2017, 'Sensitizing HR-proficient cancers to PARP inhibitors', Molecular and Cellular Oncology, 4,
    Journal articles | 2017
    Lim E; Portman N; Wahlroos S; Parker A; Segara D, 2017, 'Endocrine therapy for breast cancer: A Renaissance', The Endocrinologist, pp. 13 - 14
    Journal articles | 2017
    Meeusen E; Lim E; Mathivanan S, 2017, 'Secreted Tumor Antigens – Immune Biomarkers for Diagnosis and Therapy', Proteomics, 17,
    Journal articles | 2017
    Metzger O; Mandrekar S; Ciruelos E; Loibl S; Valagussa P; Demichele AM; Lim E; Tripathy D; Winer E; Huang C; Khoeler M; Carey L; Francis P; Miller K; Goel S; Goetz MP; Prat A; Loi S; Krop I; Gianni L, 2017, 'PATINA: A randomized open label phase III trial to evaluate the efficacy and safety of palbociclib + anti HER2 therapy + endocrine therapy vs anti HER2 therapy + endocrine therapy after induction treatment for hormone receptor positive, HER2-positive metastatic breast cancer', Annals of Oncology, 28, pp. v107 - v108,
    Journal articles | 2016
    Burgess A; Chia KM; Haupt S; Thomas D; Haupt Y; Lim E, 2016, 'Clinical overview of MDM2/X-targeted therapies', Frontiers in Oncology, 6,
    Journal articles | 2016
    Chaffer CL; San Juan BP; Lim E; Weinberg RA, 2016, 'EMT, cell plasticity and metastasis', Cancer and Metastasis Reviews, 35, pp. 645 - 654,
    Journal articles | 2016
    Johnson SF; Cruz C; Greifenberg AK; Dust S; Stover DG; Chi D; Primack B; Cao S; Bernhardy AJ; Coulson R; Lazaro JB; Kochupurakkal B; Sun H; Unitt C; Moreau LA; Sarosiek KA; Scaltriti M; Juric D; Baselga J; Richardson AL; Rodig SJ; D'Andrea AD; Balmaña J; Johnson N; Geyer M; Serra V; Lim E; Shapiro GI, 2016, 'CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast Cancer', Cell Reports, 17, pp. 2367 - 2381,
    Journal articles | 2016
    Lim E; Palmieri C; Tilley WD, 2016, 'Renewed interest in the progesterone receptor in breast cancer', British Journal of Cancer, 115, pp. 909 - 911,
    Journal articles | 2016
    Lim E; Tarulli G; Portman N; Hickey TE; Tilley WD; Palmieri C, 2016, 'Pushing estrogen receptor around in breast cancer', Endocrine-Related Cancer, 23, pp. T227 - T241,
    Journal articles | 2016
    Neupane M; Clark AP; Landini S; Birkbak NJ; Eklund AC; Lim E; Culhane AC; Barry WT; Schumacher SE; Beroukhim R; Szallasi Z; Vidal M; Hill DE; Silver DP, 2016, 'MECP2 is a frequently amplified oncogene with a novel epigenetic mechanism that mimics the role of activated RAS in malignancy', Cancer Discovery, 6, pp. 45 - 58,
    Journal articles | 2016
    Ramchand SK; Lim E; Grossmann M, 2016, 'Adjuvant endocrine therapy in women with oestrogen-receptor-positive breast cancer: how should the skeletal and vascular side effects be assessed and managed?', Clinical Endocrinology, 85, pp. 689 - 693,
    Journal articles | 2016
    Samanta S; Sun H; Goel HL; Pursell B; Chang C; Khan A; Greiner DL; Cao S; Lim E; Shultz LD; Mercurio AM, 2016, 'IMP3 promotes stem-like properties in triple-negative breast cancer by regulating SLUG', Oncogene, 35, pp. 1111 - 1121,
    Journal articles | 2015
    Chang C; Goel HL; Gao H; Pursell B; Shultz LD; Greiner DL; Ingerpuu S; Patarroyo M; Cao S; Lim E; Mao J; Kulju McKee K; Yurchenco PD; Mercurio AM, 2015, 'A laminin 511 matrix is regulated by Taz and functions as the ligand for the α6Bβ1 integrin to sustain breast cancer stem cells', Genes and Development, 29, pp. 1 - 6,
    Journal articles | 2015
    Chia KM; O’Brien M; Brown M; Lim E, 2015, 'Targeting the Androgen Receptor in Breast Cancer', Current Oncology Reports, 17,
    Journal articles | 2015
    Wang Y; Zhang T; Kwiatkowski N; Abraham BJ; Lee TI; Xie S; Yuzugullu H; Von T; Li H; Lin Z; Stover DG; Lim E; Wang ZC; Iglehart JD; Young RA; Gray NS; Zhao JJ, 2015, 'CDK7-Dependent Transcriptional Addiction in Triple-Negative Breast Cancer', Cell, 163, pp. 174 - 186,
    Journal articles | 2015
    Wee ZN; Yatim SMJM; Kohlabauer VK; Feng M; Goh JY; Bao Y; Lee PL; Zhang S; Wang PP; Lim E; Tam WL; Cai Y; Ditzel HJ; Hoon DSB; Tan EY; Yu Q, 2015, 'Erratum: IRAK1 is a therapeutic target that drives breast cancer metastasis and resistance to paclitaxel (Nature Communications (2015) 6 (8746) DOI: 10.1038/ncomms9746)', Nature Communications, 6,
    Journal articles | 2015
    Wee ZN; Yatim SMJM; Kohlbauer VK; Feng M; Goh JY; Yi B; Lee PL; Zhang S; Wang PP; Lim E; Tam WL; Cai Y; Ditzel HJ; Hoon DSB; Tan EY; Yu Q, 2015, 'IRAK1 is a therapeutic target that drives breast cancer metastasis and resistance to paclitaxel', Nature Communications, 6,
    Journal articles | 2014
    Chen X; Iliopoulos D; Zhang Q; Tang Q; Greenblatt MB; Hatziapostolou M; Lim E; Tam WL; Ni M; Chen Y; Mai J; Shen H; Hu DZ; Adoro S; Hu B; Song M; Tan C; Landis MD; Ferrari M; Shin SJ; Brown M; Chang JC; Liu XS; Glimcher LH, 2014, 'XBP1 promotes triple-negative breast cancer by controlling the HIF1α pathway', Nature, 508, pp. 103 - 107,
    Journal articles | 2014
    Hu Y; Petit SA; Ficarro SB; Toomire KJ; Xie A; Lim E; Cao SA; Park E; Eck MJ; Scully R; Brown M; Marto JA; Livingston DM, 2014, 'PARP1-driven poly-ADP-ribosylation regulates BRCA1 function in homologous recombination–mediated DNA repair', Cancer Discovery, 4, pp. 1430 - 1447,
    Journal articles | 2014
    Lim E; Lin NU, 2014, 'Updates on the management of breast cancer brain metastases', Oncology (Williston Park), 28, pp. 572 - 578
    Journal articles | 2014
    Lim E; Ni M; Cao S; Hazra A; Tamimi RM; Brown M, 2014, 'Importance of breast cancer subtype in the development of androgen-receptor-directed therapy', Current Breast Cancer Reports, 6, pp. 71 - 78,
    Journal articles | 2014
    Lu G; Zhang Q; Huang Y; Song J; Tomaino R; Ehrenberger T; Lim E; Liu W; Bronson RT; Bowden M; Brock J; Krop IE; Dillon DA; Gygi SP; Mills GB; Richardson AL; Signoretti S; Yaffe MB; Kaelin WG, 2014, 'Phosphorylation of ETS1 by src family kinases prevents its recognition by the COP1 tumor suppressor', Cancer Cell, 26, pp. 222 - 234,
    Journal articles | 2014
    Wang Y; Lee YM; Baitsch L; Huang A; Xiang Y; Tong H; Lako A; Von T; Choi C; Lim E; Min J; Li L; Stegmeier F; Schlegel R; Eck MJ; Gray NS; Mitchison TJ; Zhao JJ, 2014, 'MELK is an oncogenic kinase essential for mitotic progression in basal-like breast cancer cells', eLife, 2014,
    Journal articles | 2013
    Buchwalter G; Hickey MM; Cromer A; Selfors LM; Gunawardane RN; Frishman J; Jeselsohn R; Lim E; Chi D; Fu X; Schiff R; Brown M; Brugge JS, 2013, 'PDEF Promotes Luminal Differentiation and Acts as a Survival Factor for ER-Positive Breast Cancer Cells', Cancer Cell, 23, pp. 753 - 767,
    Journal articles | 2013
    McLaughlin SK; Olsen SN; Dake B; De Raedt T; Lim E; Bronson RT; Beroukhim R; Polyak K; Brown M; Kuperwasser C; Cichowski K, 2013, 'The RasGAP Gene, RASAL2, Is a Tumor and Metastasis Suppressor', Cancer Cell, 24, pp. 365 - 378,
    Journal articles | 2013
    Ni M; Chen Y; Fei T; Li D; Lim E; Liu XS; Brown M, 2013, 'Amplitude modulation of androgen signaling by c-MYC', Genes and Development, 27, pp. 734 - 748,
    Journal articles | 2013
    Tam WL; Lu H; Buikhuisen J; Soh BS; Lim E; Reinhardt F; Wu ZJ; Krall JA; Bierie B; Guo W; Chen X; Liu XS; Brown M; Lim B; Weinberg RA, 2013, 'Protein Kinase C α Is a Central Signaling Node and Therapeutic Target for Breast Cancer Stem Cells', Cancer Cell, 24, pp. 347 - 364,
    Journal articles | 2013
    Tichy JR; Lim E; Anders CK, 2013, 'Breast cancer in adolescents and young adults: A review with a focus on biology', JNCCN Journal of the National Comprehensive Cancer Network, 11, pp. 1060 - 1069,
    Journal articles | 2012
    Lim E; He HH; Chi D; Garber JE; Richardson A; Brown M, 2012, 'Estrogen receptor (ER) signaling in normal, BRCA (B) 1 and B2 mutation associated, and ER-positive breast cancer (BC) mammary cells.', Journal of Clinical Oncology, 30, pp. 576 - 576,
    Journal articles | 2012
    Lim E; Lin NU, 2012, 'New insights and emerging therapies in breast cancer brain metastases', Oncology (Williston Park), 26, pp. 652 - 659
    Journal articles | 2012
    Lim E; Metzger-Filho O; Winer EP, 2012, 'Natural history of hormone receptor positive breast cancer', Oncology (Williston Park), 26, pp. 688 - 694
    Journal articles | 2012
    Lim E; Ni M; Hazra A; Tamimi R; Brown M, 2012, 'Elucidating the role of androgen receptors and breast cancer.', Clinical Investigation, 2, pp. 1003 - 1011
    Journal articles | 2012
    Oakes SR; Vaillant F; Lim E; Lee L; Breslin K; Feleppa F; Deb S; Ritchie ME; Takano E; Ward T; Fox SB; Generali D; Smyth GK; Strasser A; Huang DCS; Visvader JE; Lindeman GJ, 2012, 'Sensitization of BCL-2-expressing breast tumors to chemotherapy by the BH3 mimetic ABT-737', Proceedings of the National Academy of Sciences of the United States of America, 109, pp. 2766 - 2771,
    Journal articles | 2012
    Oakes SR; Vaillant F; Lim E; Lee L; Breslin K; Feleppa F; Deb S; Ritchie ME; Takano E; Ward T; Fox SB; Generali D; Smyth GK; Strasser A; Huang DCS; Visvader JE; Lindeman GJ, 2012, 'Targeting BCL-2–expressing basal-like breast cancer with BH3-mimetics', Hereditary cancer in clinical practice, 10, pp. A25 - A25,
    Journal articles | 2012
    Shen RR; Zhou AY; Kim E; Lim E; Habelhah H; Hahn WC, 2012, 'IκB kinase ε phosphorylates TRAF2 to promote mammary epithelial cell transformation', Molecular and Cellular Biology, 32, pp. 4756 - 4768,
    Journal articles | 2011
    Lim E; Winer EP, 2011, 'Will preoperative trials change future clinical practice?', Clinical Investigation, 1, pp. 59 - 73,
    Journal articles | 2011
    Lindeman G; Asselin-Labat M-L; Lim E; Vaillant F; Wu D; Pal B; Sheridan J; Martin J; Smyth G; Visvader J, 2011, 'S17 Breast stem and progenitor cells in cancer – Therapeutic implications', The Breast, 20, pp. S6 - S6,
    Journal articles | 2011
    Ni M; Chen Y; Bailey ST; Imai Y; Liu XS; Brown M, 2011, 'Abstract 941: Targeting androgen receptor in estrogen receptor-negative breast cancer', Cancer Research, 71, pp. 941 - 941,
    Journal articles | 2011
    Ni M; Chen Y; Lim E; Wimberly H; Bailey ST; Imai Y; Rimm DL; Shirley Liu X; Brown M, 2011, 'Targeting Androgen Receptor in Estrogen Receptor-Negative Breast Cancer', Cancer Cell, 20, pp. 119 - 131,
    Journal articles | 2010
    Lim E; Wu D; Pal B; Bouras T; Asselin-Labat ML; Vaillant F; Yagita H; Lindeman GJ; Smyth GK; Visvader JE, 2010, 'Transcriptome analyses of mouse and human mammary cell subpopulations reveal multiple conserved genes and pathways', Breast Cancer Research, 12,
    Journal articles | 2010
    Wu D; Lim E; Vaillant F; Asselin-Labat ML; Visvader JE; Smyth GK, 2010, 'ROAST: Rotation gene set tests for complex microarray experiments', Bioinformatics, 26, pp. 2176 - 2182,
    Journal articles | 2009
    Lim E; Vaillant F; Wu D; Forrest N; Pal B; Gyorki D; Smyth GK; Visvader J; Lindeman G, 2009, 'Investigation of human mammary stem and progenitor subpopulations from BRCA1 mutation carriers and noncarriers', Journal of Clinical Oncology, 27, pp. 504 - 504,
    Journal articles | 2009
    Lim E; Vaillant F; Wu D; Forrest NC; Pal B; Hart AH; Asselin-Labat ML; Gyorki DE; Ward T; Partanen A; Feleppa F; Huschtscha LI; Thorne HJ; Fox SB; Yan M; French JD; Brown MA; Smyth GK; Visvader JE; Lindeman GJ, 2009, 'Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers', Nature Medicine, 15, pp. 907 - 913,
    Journal articles | 2007
    Lim E; Rosenthal MA, 2007, 'Diagnosing cancer: changing patterns of care', INTERNAL MEDICINE JOURNAL, 37, pp. 124 - 126,
    Journal articles | 2007
    Lim E; Thomson BNJ; Heinze S; Chao M; Gunawardana D; Gibbs P, 2007, 'Optimizing the approach to patients with potentially resectable liver metastases from colorectal cancer', ANZ Journal of Surgery, 77, pp. 941 - 947,
    Journal articles | 2006
    Lim E; Browning J; MacGregor D; Davis ID; Cebon JS, 2006, 'Antigen expression in desmoplastic melanoma: a comparison of cancer testis antigen with differentiation antigen expression', Melanoma Research: an international journal of rapid communications of basic and clinical research in melanoma, 16, pp. 347 - 355,
    Journal articles | 2006
    Rodrigues J; Lim E; McLaughlin S; Faragher I; Skinner I; Chao M; Chapman M; Gibbs P, 2006, 'The influence of language spoken on colorectal cancer diagnosis and management [2]', ANZ Journal of Surgery, 76, pp. 671 - 672,
    Journal articles | 2005
    Lim E; Johns J; McLaughlin S; Faragher I; Skinner I; Chao M; Gibbs P, 2005, 'Subsite-Specific Colorectal Cancer in Diabetic and Nondiabetic Patients', Cancer Epidemiology Biomarkers & Prevention, 14, pp. 1579 - 1582,
    Journal articles | 2004
    Lim E; Wicks I; Roberts LJ, 2004, 'Intracardiac thrombosis complicating antiphospholipid antibody syndrome.', Intern Med J, 34, pp. 135 - 137,
  • Preprints | 2023
    Hurwitz J; Haggstrom LR; Lim E, 2023, Antibody Drug Conjugates: Ushering in a New Era of Cancer Therapy, ,
    Preprints | 2023
    Wang T; Harvey K; Reeves J; Roden DL; Bartonicek N; Yang J; Al-Eryani G; Kaczorowski D; Chan C-L; Powell J; O’Toole S; Lim E; Swarbrick A, 2023, An experimental comparison of the Digital Spatial Profiling and Visium spatial transcriptomics technologies for cancer research, ,
    Conference Abstracts | 2022
    Freelander A; Laven-Law G; Eshraghi L; Chia KM; Pickering M; Yong A; Wilkinson A; Alexandrou S; Caldon CE; Hickey TE; Tilley WD; Lim E, 2022, 'Combination CDK4/6 inhibition and AR agonism suppresses the growth of CDK4/6 inhibitor resistant breast cancers', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, Vol. 82,
    Conference Abstracts | 2022
    Jhaveri KL; Jeselsohn R; Lim E; Hamilton EP; Yonemori K; Beck JT; Kaufman PA; Sammons S; Bhave MA; Saura C; Calvo E; Meniawy T; Larson T; Ma CX; García-Corbacho J; Cao S; Estrem ST; Milata JL; Nguyen B; Beeram M, 2022, 'A phase 1a/b trial of imlunestrant (LY3484356), an oral selective estrogen receptor degrader (SERD) in ER-positive (ER+) advanced breast cancer (aBC) and endometrial endometrioid cancer (EEC): Monotherapy results from EMBER.', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 40, pp. 1021 - 1021,
    Preprints | 2022
    Lim E; Boyle F; Okera M; Loi S; Goksu SS; Hal GV; Chapman S; Gable J; Chen Y; Price G; Hossein A; Gainford C; Ezquerra MB, 2022, An open label, randomized phase 2 trial assessing the impact of food on the tolerability of abemaciclib in patients with Advanced Breast Cancer, ,
    Conference Abstracts | 2022
    Lim E; Brufsky A; Rugo HS; Vogel CL; O'Shaughnessy J; Getzenberg RH; Barnette KG; Rodriguez D; Bird G; Steiner MS; Linden HM, 2022, 'Phase 3 ENABLAR-2 study to evaluate enobosarm and abemaciclib combination compared to estrogen-blocking agent for the second-line treatment of AR+, ER+, HER2- metastatic breast cancer in patients who previously received palbociclib and estrogen-blocking agent combination therapy.', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 40, pp. TPS1121 - TPS1121,
    Preprints | 2022
    San Juan B; Hediyeh-Zadeh S; Rangel L; Milioli H; Rodriguez V; Bunkum A; Kohane F; Purcell C; Bhuva D; Kurumlian A; Castillo L; Lim E; Gill A; Ganju V; Dear R; O’Toole S; Vargas C; Hickey T; Goldstein L; Lock J; Davis M; Chaffer C, 2022, Targeting phenotypic plasticity prevents metastasis and the development of chemotherapy-resistant disease,
    Conference Posters | 2022
    Turner NC; Loi S; Moore HM; Chang C-W; Eng-Wong J; Bardia A; Boni V; Sohn J; Jhaveri KL; Lim E, 2022, 'Abstract PD13-07: Activity and biomarker analyses from a phase Ia/b study of giredestrant (GDC-9545; G) with or without palbociclib (palbo) in patients with estrogen receptor-positive, HER2-negative locally advanced/metastatic breast cancer (ER+/HER2- LA/mBC)', Vol. 82,
    Preprints | 2022
    Wahlroos S; Portman N; Bonder C; Hjorth M; Wilkinson A; Hastings J; Croucher D; Febbraio M; Gallego-Ortega D; Lim E, 2022, Exercise-induced modulation of the immune microenvironment in pre-clinical breast cancer models., ,
    Conference Abstracts | 2022
    Wong K; Sheehan-Dare G; Nguyen A; Ho B; Liu V; Lee J; Brown LJ; Dear RF-G; Chan L; Pathmanandavel S; Sharma S; Malaroda A; Smith I; Lim E; Emmett L, 2022, '64Cu-SAR-Bombesin PET-CT imaging in the staging of ER+/PR+/HER2- metastatic breast cancer: Safety, dosimetry, and feasibility in a phase I trial.', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 40, pp. 3092 - 3092,
    Conference Abstracts | 2021
    Brown LJ; Meredith T; Yu J; Patel A; Neal B; Arnott C; Lim E, 2021, 'Heart failure therapies for the prevention of HER2-monoclonal antibody-mediated cardiotoxicity: A systematic review and meta-analysis', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, Vol. 17, pp. 119 - 119,
    Conference Papers | 2021
    Lau B; Segara D; Ong A; Bingham J; Kiely B; Carson E-K; Chen J; Mak C; Warrier S; Hui M; Middleton K; Parker A; Mann B; Lindeman G; Tilley W; Lim E, 2021, 'Abstract OT-09-07: Winpro: A window of opportunity study of endocrine therapy with and without prometrium in postmenopausal women with early stage hormone receptor-positive breast cancer', in Cancer Research, American Association for Cancer Research (AACR), presented at Abstracts: 2020 San Antonio Breast Cancer Virtual Symposium; December 8-11, 2020; San Antonio, Texas,
    Conference Abstracts | 2021
    Lau B; Segara D; Ong A; Bingham J; Kiely B; Carson E-K; Chen J; Mak C; Warrier S; Hui M; Middleton K; Parker A; Mann B; Lindeman G; Tilley W; Lim E, 2021, 'Winpro: A window of opportunity study of endocrine therapy with and without prometrium in postmenopausal women with early stage hormone receptor-positive breast cancer', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, Vol. 81,
    Conference Papers | 2021
    Lim E; Beeram M; Prawira A; Patnaik A; Wang XA; Young SRL; Smyth LM; Hamilton EP, 2021, 'Abstract OT-09-03: EMBER: A phase 1a/b trial of LY3484356, a novel, oral selective estrogen-receptor degrader (SERD), in advanced ER+ breast cancer and endometroid endometrial cancer', in Cancer Research, American Association for Cancer Research (AACR),
    Conference Abstracts | 2021
    Lim E; Beeram M; Prawira A; Patnaik A; Wang XA; Young SRL; Smyth LM; Hamilton EP, 2021, 'EMBER: A phase 1a/b trial of LY3484356, a novel, oral selective estrogen-receptor degrader (SERD), in advanced ER plus breast cancer and endometroid endometrial cancer', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, Vol. 81,
    Conference Abstracts | 2021
    Moore HM; Boni V; Bellet M; De Las Heras BB; Cortes MG; Oakman C; Schmid P; Trinh XB; Wheatley D; Jhaveri KL; Kabos P; Lim E; Velu T; Metcalfe C; Gates MR; Chang C-W; Bond J; Goldstein LD; Lauchle JO; Bardia A, 2021, 'Evaluation of pharmacodynamic (PD) and biologic activity in a preoperative window-of-opportunity (WOO) study of giredestrant (GDC-9545) in postmenopausal patients (pts) with estrogen receptor-positive, HER2-negative (ER+/HER2-) operable breast cancer (BC).', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, Vol. 39,
    Conference Abstracts | 2021
    Palmieri C; Linden H; Birrell S; Lim E; Schwartzberg LS; Rugo HS; Cobb P; Jain K; Vogel C; O'Shaughnessy J; Johnston SRD; Getzenberg RH; Barnette KG; Steiner M; Brufsky AM; Overmoyer B, 2021, 'Efficacy of enobosarm, a selective androgen receptor (AR) targeting agent, in patients with metastatic AR plus /ER plus breast cancer resistant to estrogen receptor targeted agents and CDK 4/6 inhibitor in a phase II clinical study', in ANNALS OF ONCOLOGY, ELSEVIER, ELECTR NETWORK, Vol. 32, pp. S66 - S66, presented at ESMO Breast Cancer Virtual Congress, ELECTR NETWORK, 05 May 2021 - 08 May 2021,
    Conference Papers | 2021
    Palmieri C; Linden H; Birrell S; Lim E; Schwartzberg LS; Rugo HS; Cobb P; Jain K; Vogel C; O’Shaughnessy JA; Getzenberg RH; Steiner MS; Brufsky A; Overmoyer B, 2021, 'Abstract PD8-10: Efficacy and safety of enobosarm, a selective androgen receptor modulator, to target AR in women with advanced ER+/AR+ breast cancer - final results from an international Phase 2 randomized study', in Cancer Research, American Association for Cancer Research (AACR), presented at Abstracts: 2020 San Antonio Breast Cancer Virtual Symposium; December 8-11, 2020; San Antonio, Texas,
    Conference Papers | 2021
    Portman N; Milioli H; Alexandrou S; Coulson R; Yong A; Fernandez K; Chia K; Halilovic E; Segara D; Parker A; Haupt S; Haupt Y; Tilley W; Swarbrick A; Caldon L; Lim E, 2021, 'Abstract PS18-17: Mdm2 inhibition synergises with endocrine therapy or cdk4/6 inhibition for the treatment of estrogen receptor-positive breast cancer', in Cancer Research, American Association for Cancer Research (AACR), presented at Abstracts: 2020 San Antonio Breast Cancer Virtual Symposium; December 8-11, 2020; San Antonio, Texas,
    Conference Abstracts | 2021
    Portman N; Milioli H; Alexandrou S; Coulson R; Yong A; Fernandez K; Chia K; Halilovic E; Segara D; Parker A; Haupt S; Haupt Y; Tilley W; Swarbrick A; Caldon L; Lim E, 2021, 'Mdm2 inhibition synergises with endocrine therapy or cdk4/6 inhibition for the treatment of estrogen receptor-positive breast cancer', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, Vol. 81,
    Conference Abstracts | 2021
    Sheehan-Dare G; Lim E; Koo CM; Chan L; Lau B; Dear R; Ho B; Sharma S; Hickey A; Malaroda A; Smith I; Nguyen A; Parker M; Emmett L, 2021, 'Preliminary assessment of the diagnostic value of Cu-64-SAR-Bombesin PET-CT imaging for staging of ER+/PR+HER2-metastatic breast cancer disease: comparison with conventional imaging', in JOURNAL OF NUCLEAR MEDICINE, SOC NUCLEAR MEDICINE INC, Vol. 62,
    Conference Abstracts | 2021
    Wong V; De Boer R; Baron-Hay S; Blum R; Forster B; Chua S; Clarke K; Cuff K; Green M; Lim E; Mok K; Nott LW; Nottage M; Tafreshi A; Tsoi D; Uccelini A; Gibbs P; Lok SW, 2021, 'Patient-reported outcomes of medicine access programmes: A sub-study of KARMA (Kisqali Access Registry for Metastatic Breast Cancer in Australia)', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, Vol. 17, pp. 175 - 176,
    Conference Abstracts | 2021
    Wu SZ; Roden D; Al Eryani G; Junankar S; Lim E; Thennavan A; Andersson A; Williams S; Gong J; Fropf R; Fuhrman K; Lundeberg J; Perou C; Swarbrick A, 2021, 'An integrated multi-omic cellular atlas of human breast cancers.', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, Vol. 81,
    Conference Papers | 2021
    Wu SZ; Roden D; Eryani GA; Junankar S; Lim E; Thennavan A; Andersson A; Williams S; Gong J; Fropf R; Fuhrman K; Lundeberg J; Perou C; Swarbrick A, 2021, 'Abstract 129: An integrated multi-omic cellular atlas of human breast cancers', in Cancer Research, American Association for Cancer Research (AACR), pp. 129 - 129,
    Conference Abstracts | 2021
    Yap Y-S; Kim S-B; Chiu JWY; Lim E; Broom R; Liu Z; Sagara Y; Chao T-Y; Sherwood S; McNaughton RE; Wei RJ; Toi M, 2021, 'Abemaciclib combined with adjuvant endocrine therapy in patients from Asia with high risk early breast cancer: monarchE', in ANNALS OF ONCOLOGY, ELSEVIER, ELECTR NETWORK, Vol. 32, pp. S41 - S42, presented at ESMO Breast Cancer Virtual Congress, ELECTR NETWORK, 05 May 2021 - 08 May 2021,
    Preprints | 2020
    Aziz D; Portman N; Fernandez KJ; Lee C; Alexandrou S; Llop-Guevara A; Yong A; Wilkinson A; Sergio CM; Ferraro D; Etemadmoghadam D; Bowtell D; Investigators K; Serra V; Waring P; Lim E; Caldon CE, 2020, Cyclin E1 protein is stabilized inBRCA1mutated breast cancers leading to synergy between CDK2 and PARP inhibitors, ,
    Preprints | 2020
    Baker LA; Holliday H; Roden D; Krisp C; Wu SZ; Junankar S; Serandour AA; Mohammed H; Nair R; Sankaranarayanan G; Law AMK; McFarland A; Simpson PT; Lakhani S; Dodson E; Selinger C; Anderson L; Samimi G; Hacker NF; Lim E; Ormandy CJ; Naylor MJ; Simpson K; Nikolic I; O’Toole S; Kaplan W; Cowley MJ; Carroll JS; Molloy M; Swarbrick A, 2020, Proteogenomic analysis of Inhibitor of Differentiation 4 (ID4) in basal-like breast cancer, ,
    Preprints | 2020
    Baker LA; Holliday H; Roden D; Krisp C; Wu SZ; Junankar S; Serandour AA; Mohammed H; Nair R; Sankaranarayanan G; Law AMK; McFarland A; Simpson PT; Lakhani S; Dodson E; Selinger C; Anderson L; Samimi G; Hacker NF; Lim E; Ormandy CJ; Naylor MJ; Simpson K; Nikolic I; O’Toole S; Kaplan W; Cowley MJ; Carroll JS; Molloy M; Swarbrick A, 2020, Proteogenomic analysis of Inhibitor of Differentiation 4 (ID4) in basal-like breast cancer, ,
    Preprints | 2020
    Gemma C; Lai C-F; Singh AK; Belfiore A; Portman N; Milioli HZ; Periyasamy M; Abuelmaaty S; Nicholls AJ; Davies CM; Patel NR; Simmons GM; Fan H; Nguyen VTM; Magnani L; Rakha E; Martin L-A; Lim E; Coombes RC; Pruneri G; Buluwela L; Ali S, 2020, VGLL1 drives therapy resistance in estrogen receptor positive breast cancer, ,
    Conference Abstracts | 2020
    Hickey T; Selth L; Chia KM; Milioli HH; Laven-Law G; Roden D; Jindal S; Hui M; Ebrahimie E; Birrel SN; Stello S; Iggo R; Alexandrou S; Caldon L; Finlay-Shultz J; Abdel-Fatah TM; Ellis IO; Zwart W; Palmieri C; Sartorious CA; Swarbrick A; Lim E; Carrol JS; Tilley WD, 2020, 'The androgen receptor is a tumour suppressor in estrogen receptor positive breast cancer', in Journal of the Endocrine Society, Oxford University Press (OUP), Vol. 4, pp. or05 - or06, presented at Endocrine Society Annual Meeting,
    Conference Papers | 2020
    Lim E; Boyle F; Okera M; Loi S; Goksu SS; van Hal G; Gable JC; Price GL; Hossain A; Gainford M; Ezquerra MB, 2020, 'The impact of food on tolerability of abemaciclib in patients with previously treated hormone receptor-positive, HER2-negative, metastatic breast cancer: An open-label, randomized phase 2 study', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, pp. 124 - 125,
    Conference Papers | 2020
    Lim E; Milioli HH; Alexandrou S; Coulson R; Yong A; Fernandez KJ; Chia K; Halilovic E; Segara D; Parker A; Haupt S; Haupt Y; Tilley WD; Swarbrick A; Caldon EC; Portman N, 2020, 'MDM2 inhibition in combination with endocrine therapy and CDK4/6 inhibition for the treatment of ER-positive breast cancer', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, pp. 110 - 110,
    Conference Abstracts | 2020
    Lim E, 2020, 'A phase Ib study to evaluate the oral selective estrogen receptor degrader GDC-9545 alone or combined with palbociclib in metastatic ER-positive HER2-negative breast cancer.', in Journal of Clinical Oncology, American Society of Clinical Oncology, Chicago, presented at American Society of Clinical Oncology, Chicago, 29 May 2020 - 31 May 2020
    Conference Abstracts | 2020
    Palmieri C; Linden H; Birrell S; Lim E; Schwartzberg LS; Rugo HS; Cobb P; Jain K; Vogel C; O'Shaughnessy JA; Getzenberg RH; Steiner MS; Brufsky A; Overmoyer B, 2020, 'Efficacy and safety of enobosarm, a selective androgen receptor modulator, to target AR in women with advanced ER plus /AR plus breast cancer - final results from an international Phase 2 randomized study', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, ELECTR NETWORK, Vol. 81, presented at San Antonio Breast Cancer Virtual Symposium, ELECTR NETWORK, 08 December 2020 - 11 December 2020,
    Preprints | 2020
    Tilley W; Hickey T; Selth L; Chia KM; Milioli H; Laven-Law G; Roden D; Jindal S; Hui M; Finlay-Schultz J; Ebrahimie E; Birrell S; Stelloo S; Iggo R; Alexandrou S; Caldon C; Abdel-Fatah T; Ellis I; Zwart W; Palmieri C; Sartorius C; Swarbrick A; Lim E; Carroll J, 2020, The Androgen Receptor is a Tumour Suppressor in Estrogen Receptor Positive Breast Cancer, ,
    Conference Abstracts | 2019
    Alexandrou S; Milioli HH; Portman N; Lee C; Fernandez K; Blake D; Lim E; Caldon L, 2019, 'S phase dysregulation occurs following resistance to CDK4/6 inhibition ER+ breast cancer', in Oncolabs, presented at 7th PacRim Breast & Prostate Cancer Meeting,
    Conference Abstracts | 2019
    Chia KM; Milioli HH; Portman N; Laven-Law G; Coulson R; Young A; Segara D; Parker A; Caldon L; Deng N; Swarbrick A; Tilley W; Hickey T; Lim E, 2019, 'Targeting AR in endocrine-resistant breast cancer', in Oncolabs, presented at 7th PacRim Breast & Prostate Cancer Meeting,
    Conference Abstracts | 2019
    Jhaveri K; Winer EP; Lim E; Fidalgo JA; Bellet M; Mayer IA; Boni V; Patel JM; Bardia A; Garcia JM; Kabos P; Gates M; Chen Y-C; Fredrickson J; Wang X; Friedman LS; Spoerke J; Gendreau S; Metcalfe C; Liu L; Chang C-W; Monemi S; Gonzalez M; McCurry U; Milan S; Humke EW; Loi S, 2019, 'A first-in-human phase I study to evaluate the oral selective estrogen receptor degrader (SERD), GDC-9545, in postmenopausal women with estrogen receptor-positive (ER+) HER2-negative (HER2-) metastatic breast cancer', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, TX, San Antonio, Vol. 80, presented at 42nd Annual San Antonio Breast Cancer Symposium, TX, San Antonio, 09 December 2019 - 14 December 2019,
    Conference Abstracts | 2019
    Lim E; Boyle F; Okera M; Loi S; Goksu SS; van Hal G; Hartman DG; Gable JC; Price GL; Hossain A; Gainford MC; Ezquerra MB, 2019, 'The impact of food on tolerability of abemaciclib in patients with previously treated hormone receptor-positive, HER2-negative, metastatic breast cancer: An open-label, randomized phase 2 study', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, TX, San Antonio, Vol. 80, presented at 42nd Annual San Antonio Breast Cancer Symposium, TX, San Antonio, 09 December 2019 - 14 December 2019,
    Conference Abstracts | 2019
    Lim E; Hickey TA; Selth LA; Chia KM; Milioli HH; Roden D; Laven-Law G; Jindal S; Hui M; Ebrahimie E; Birrell SN; Stelloo S; Caldon CE; Finlay-Schultz J; Abdel-Fatah TM; Ellis IO; Zwart W; Palmieri C; Sartorius CA; Swarbrick A; Carroll JS; Tilley WD, 2019, 'The androgen receptor is a tumour suppressor in estrogen receptor positive breast cancer', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, TX, San Antonio, Vol. 80, presented at 42nd Annual San Antonio Breast Cancer Symposium, TX, San Antonio, 09 December 2019 - 14 December 2019,
    Conference Abstracts | 2019
    Lok SW; Baron-Hay S; Lim E; Blum R; Boyle F; Clarke K; Cuff K; Green M; Malik L; Mok K; Murray N; Nott L; Nottage M; Tafreshi A; Tsoi D; Yeo B; Gibbs P; De Boer R, 2019, 'A 'real world' experience of CDK4/6 inhibition with ribociclib and endocrine therapy in hormone receptor positive metastatic breast cancer in Australia', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, TX, San Antonio, Vol. 80, presented at 42nd Annual San Antonio Breast Cancer Symposium, TX, San Antonio, 09 December 2019 - 14 December 2019,
    Conference Abstracts | 2019
    Milioli HH; Chia KM; Portman N; Young A; Laven-Law G; Selth L; Tilley WD; Hickey T; Lim E, 2019, 'Androgen receptor activation in Endocrine-Resistant ER-positive breast cancer', in Oncolabs, presented at 7th PacRim Breast & Prostate Cancer Meeting,
    Conference Abstracts | 2019
    Portman N; Milioli HH; Young A; Coulson R; Alexandrou S; Lam N; Haup S; Haup Y; Caldon L; Deng N; Lim E, 2019, 'Activation of p53 in combination with endocrine and CDK targeted therapies in ER+ breast cancer', in Oncolabs, presented at 7th PacRim Breast & Prostate Cancer Meeting,
    Conference Abstracts | 2019
    Stirzaker C; Chia KM; Portman N; Milioli HH; Clifton S; Achinger-Kawecka J; Nair S; Lim E; Clark S, 2019, 'DNA demethylation agents as a therapeutic approach in endocrine-resistant breast cancer', in Oncolabs, presented at 7th PacRim Breast & Prostate Cancer Meeting,
    Conference Abstracts | 2019
    Wahlroos S; Wilkinson A; Milioli H; Portman N; Gallego-Ortega D; Lim E, 2019, 'Concurrent exercise and chemotherapy in preclinical breast cancer models', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, TX, San Antonio, Vol. 80, presented at 42nd Annual San Antonio Breast Cancer Symposium, TX, San Antonio, 09 December 2019 - 14 December 2019,
    Conference Abstracts | 2018
    Carson E; Segara D; Parker A; O'Toole S; Coates A; Mann B; Lindeman G; Tilley W; Lim E, 2018, 'The WinPro study: A window of opportunity study of endocrine therapy with and without prometrium in postmenopausal women with early stage hormone receptor-positive breast cancer', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, TX, San Antonio, Vol. 79, presented at San Antonio Breast Cancer Symposium, TX, San Antonio, 04 December 2018 - 08 December 2018,
    Conference Abstracts | 2018
    Chia KM; Milioli H; Portman N; Laven-Law G; Yong A; Swarbrick A; Caldon L; Tilley W; Hickey T; Lim E, 2018, 'Activation of AR inhibits growth of endocrine-resistant breast cancer', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, TX, San Antonio, Vol. 79, presented at San Antonio Breast Cancer Symposium, TX, San Antonio, 04 December 2018 - 08 December 2018,
    Conference Abstracts | 2018
    Lim E; Carson E, 2018, 'The WinPro study: A window of opportunity study of endocrine therapy with and without prometrium in postmenopausal women with early stage hormone receptor-positive breast cancer', in Asia-Pacific Journal of Clinical Oncology, Wiley, Perth Convention and Exhibition Centre, Perth, Western Australia, Vol. 14, pp. 194 - 195, presented at COSA's 45th Annual Scientific Meeting, Perth Convention and Exhibition Centre, Perth, Western Australia, 13 November 2018 - 15 November 2018,
    Conference Papers | 2018
    Lim E; Portman N; Alexandrou S; Haupt S; Haupt Y; Caldon E, 2018, 'Abstract P4-04-12: Therapeutic targeting of CDK4/6 inhibitor resistant breast cancer', in Cancer Research, American Association for Cancer Research (AACR), presented at Abstracts: 2017 San Antonio Breast Cancer Symposium; December 5-9, 2017; San Antonio, Texas,
    Conference Abstracts | 2018
    Loibl S; Metzger O; Mandrekar SJ; Mundhenke C; Seiler S; Valagussa P; DeMichele A; Lim E; Tripathy D; Winer EP; Huang C; Carey L; Francis P; Miller KD; Goetz MP; Prat A; Loi S; Krop I; Gianni L; Ciruelos EM, 2018, 'PATINA: A randomized, open label, phase III trial to evaluate the efficacy and safety of palbociclib + Anti-HER2 therapy + endocrine therapy (ET) vs. anti-HER2 therapy + ET after induction treatment for hormone receptor positive (HR+)/HER2-positive metastatic breast cancer (MBC)', in Annals of oncology : official journal of the European Society for Medical Oncology, OXFORD UNIV PRESS, Madrid, SPAIN, Vol. 29, pp. viii121, presented at 42nd European-Society-for-Medical-Oncology Congress (ESMO), Madrid, SPAIN, 08 September 2017 - 12 September 2017,
    Conference Abstracts | 2018
    Loibl S; Metzger O; Mandrekar SJ; Mundhenke C; Seiler S; Valagussa P; DeMichele A; Lim E; Tripathy D; Winer EP; Huang C; Carey L; Francis P; Miller KD; Goetz MP; Prat A; Loi S; Krop I; Gianni L; Ciruelos EM, 2018, 'PATINA: A randomized, open label, phase III trial to evaluate the efficacy and safety of palbociclib + Anti-HER2+therapy plus endocrine therapy (ET) vs. anti-HER2 therapy + ET after induction treatment for hormone receptor positive (HR1)/HER2-positive metastatic breast cancer (MBC)', in ANNALS OF ONCOLOGY, OXFORD UNIV PRESS, GERMANY, Munich, Vol. 29, pp. 121 - 121, presented at 43rd ESMO Congress (ESMO), GERMANY, Munich, 19 October 2018 - 23 October 2018,
    Conference Abstracts | 2018
    Metzger O; Mandrekar S; Loibl S; Mundhenke C; Seiler S; Valagussa P; Lim E; Tripathy D; Winer EP; Huang C; Carey L; Francis P; Miller K; Goetz MP; Prat A; Loi S; Krop I; Gianni L; Delalogue S; Vaz-Luis I; Dockter T; Lanzillotti J; Ciruelos E; DeMichele AM, 2018, 'PATINA: A randomized, open label, phase III trial to evaluate the efficacy and safety of palbociclib+antiHER2 therapy + endocrine therapy (ET) vs. anti-HER2 therapy + ET after induction treatment for hormone receptor positive (HR+)/HER2-positive metastatic breast cancer (MBC)', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, TX, San Antonio, Vol. 79, presented at San Antonio Breast Cancer Symposium, TX, San Antonio, 04 December 2018 - 08 December 2018,
    Conference Papers | 2018
    Metzger-Filho O; Mandrekar S; Loibl S; Ciruelos E; Gianni L; Lim E; Miller K; Huang C; Koehler M; Francis P; Valagussa P; Goel S; Prat A; Goetz M; Loi S; Krop I; Carey L; Lanzillotti J; Winer E; Tripathy D; DeMichele A, 2018, 'Abstract OT3-05-07: PATINA: A randomized open label phase III trial to evaluate the efficacy and safety of palbociclib + anti HER2 therapy + endocrine therapy vs anti HER2 therapy + endocrine therapy after induction treatment for hormone receptor positive, HER2 positive metastatic breast cancer', in Cancer Research, American Association for Cancer Research (AACR), presented at Abstracts: 2017 San Antonio Breast Cancer Symposium; December 5-9, 2017; San Antonio, Texas,
    Conference Abstracts | 2018
    Swarbrick A; Cazet A; Hui M; O'Toole S; Lim E; Martin M, 2018, 'Small molecule inhibition of smoothened in triple negative breast cancer-associated fibroblasts depletes cancer stem cells and sensitizes to cytotoxic chemotherapy in mice and humans', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, TX, San Antonio, Vol. 79, presented at San Antonio Breast Cancer Symposium, TX, San Antonio, 04 December 2018 - 08 December 2018,
    Conference Abstracts | 2018
    Swarbrick A; Wu SZ; Roden D; Al-Eryani G; O'Toole S; Lim E, 2018, 'Landscape of the breast tumour microenvironment at single-cell resolution', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, TX, San Antonio, Vol. 79, presented at San Antonio Breast Cancer Symposium, TX, San Antonio, 04 December 2018 - 08 December 2018,
    Conference Abstracts | 2018
    Wahlroos S; Wilkinson A; Gallego-Ortega D; Febbraio M; Lim E, 2018, 'Concurrent exercise and chemotherapy in preclinical breast cancer models', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, TX, San Antonio, Vol. 79, presented at San Antonio Breast Cancer Symposium, TX, San Antonio, 04 December 2018 - 08 December 2018,
    Conference Abstracts | 2017
    Anderson RL; Swarbrick A; Johnstone R; Chua B; Gill A; Saunders C; Lakhani S; Lim E; Loi S; O'Toole SA; Khanna KK; Devereux L; Harvey K; Reed AM, 2017, 'Brocade: The National Breast Cancer Foundation Repository of Primary Tumours and Metastases from Breast Cancer Patients', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, Vol. 13, pp. 110 - 111,
    Preprints | 2017
    Cazet A; Hui M; Elsworth B; Wu S; Roden D; Chan C-L; Skhinas J; Collot R; Yang J; Harvey K; Johan Z; Cooper C; Nair R; Herrmann D; McFarland A; Deng N-T; Ruiz-Borrego M; Rojo F; Trigo J; Bezares S; Caballero R; Lim E; Timpson P; O’Toole S; Watkins N; Cox T; Samuel M; Martín M; Swarbrick A, 2017, Targeting stromal remodeling and cancer stem cell plasticity to overcome chemoresistance in triple negative breast cancer,
    Conference Abstracts | 2017
    Lim E; Portman N; Alexandrou S; Haupt S; Haupt Y; Caldon E, 2017, 'Therapeutic targeting of CDK4/6 inhibitor resistant breast cancer', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, TX, San Antonio, Vol. 78, presented at San Antonio Breast Cancer Symposium, TX, San Antonio, 05 December 2017 - 09 December 2017,
    Conference Abstracts | 2017
    Lin FP-Y; Martin C; Kocbek S; Joshua AM; Dear RF-G; Lim E; Chantrill LA; Chin VT; Epstein RJ, 2017, 'Identifying determinants of quality of life in patients undergoing systemic therapy for solid tumors.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, Vol. 35, presented at 53rd Annual Clinical Science Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Symposium on Old Targets, New Drugs - Her2 and MET, IL, Chicago, 02 June 2017 - 07 June 2017,
    Conference Papers | 2017
    Singhal H; Chi D; Lim E; He H; Vadhi R; Rao PK; Long HW; Richardson AL; Garber J; Brown M, 2017, 'Abstract LB-257: Estrogen signaling in mature luminal and luminal progenitor cells of BRCA2 carriers and non-carriers', in Cancer Research, American Association for Cancer Research (AACR), presented at Proceedings: AACR Annual Meeting 2017; April 1-5, 2017; Washington, DC,
    Conference Abstracts | 2016
    Lim E, 2016, 'TRANSLATING MOLECULAR INSIGHTS IN ESTROGEN RECEPTOR SIGNALING INTO CLINICAL TRIALS IN BREAST CANCER', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY-BLACKWELL, Vol. 12, pp. 82 - 83,
    Conference Abstracts | 2016
    Seah D; Robinson D; Churilov L; Lin NU; Lim E, 2016, 'ATTITUDES OF PATIENTS WITH METASTATIC CANCER TOWARD RESEARCH BIOPSIES', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, Vol. 12, pp. 107 - 108,
    Conference Abstracts | 2014
    Cao SA; Lim E; Brown M; Bailey ST, 2014, 'Modeling chemoendocrine therapy for ER+/p53wt luminal breast cancer', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, TX, San Antonio, Vol. 75, presented at 37th Annual CTRC-AACR San Antonio Breast Cancer Symposium, TX, San Antonio, 09 December 2014 - 13 December 2014,
    Conference Papers | 2014
    Johnson S; Johnson N; Chi D; Primack B; Cruz C; Stover D; Greifenberg AK; Cao S; O'Connor K; Baselga J; Balmana J; Serra V; Geyer M; D'Andrea A; Lim E; Shapiro GI, 2014, 'Reversal of primary and acquired PARP-inhibitor resistance in BRCA-mutated triple-negative breast cancers by inhibition of transcriptional cyclin-dependent kinases (CDKs)', in EUROPEAN JOURNAL OF CANCER, ELSEVIER SCI LTD, SPAIN, European Org Res & Treatment Canc, Barcelona, pp. 80 - 80, presented at 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, SPAIN, European Org Res & Treatment Canc, Barcelona, 18 November 2014 - 21 November 2014,
    Conference Abstracts | 2013
    Chi D; He H; Yeung T; Jeselsohn R; Schnitt S; Garber J; Richardson A; Lim E; Brown M, 2013, 'Abstract 2313: Differences in estrogen receptor signaling in normal mammary epithelial cells and ER-positive primary breast tumors and metastases.', in Cancer Research, American Association for Cancer Research (AACR), Vol. 73, pp. 2313 - 2313, presented at Proceedings: AACR 104th Annual Meeting 2013; Apr 6-10, 2013; Washington, DC,
    Conference Abstracts | 2013
    Johnson SF; Johnson N; Chi D; Primack B; D'Andrea AD; Lim E; Shapiro GI, 2013, 'The CDK inhibitor dinaciclib sensitizes triple-negative breast cancer cells to PARP inhibition', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, Washington, DC, Vol. 73, presented at 104th Annual Meeting of the American-Association-for-Cancer-Research (AACR), Washington, DC, 06 April 2013 - 10 April 2013,
    Conference Papers | 2012
    Lim E; He HH; Chi D; Garber JE; Richardson A; Brown M, 2012, 'Estrogen receptor (ER) signaling in normal, BRCA (B) 1 and B2 mutation associated, and ER-positive breast cancer (BC) mammary cells.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 01 June 2012 - 06 June 2012,
    Conference Papers | 2011
    Lim E; Winer EP, 2011, 'Adjuvant chemotherapy in luminal breast cancers', in Breast,
    Conference Papers | 2011
    Lindeman GJ; Oakes SR; Vaillant F; Lim E; Lee L; Breslin K; Feleppa F; Deb S; Ritchie ME; Takano E; Ward T; Fox SB; Generali D; Smyth GK; Strasser A; Huang DCS; Visvader JE, 2011, 'PD08-02: Targeting BCL-2 Expressing Breast Tumors with BH3-Mimetics – A New Class of Drugs in Breast Cancer?', in Cancer Research, American Association for Cancer Research (AACR), presented at Abstracts: Thirty-Fourth Annual CTRC‐AACR San Antonio Breast Cancer Symposium‐‐ Dec 6‐10, 2011; San Antonio, TX,
    Conference Papers | 2011
    Lindeman GJ; Oakes SR; Vaillant F; Lim E; Lee L; Breslin K; Feleppa F; Deb S; Ritchie ME; Takano E; Ward T; Fox SB; Generali D; Smyth GK; Strasser A; Huang DCS; Visvader JE, 2011, 'Targeting BCL-2 Expressing Breast Tumors with BH3-Mimetics - A New Class of Drugs in Breast Cancer?', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH,
    Conference Papers | 2011
    Visvader JE; Asselin-Labat M-L; Vaillant F; Lim E; Bouras T; Pal B; Wu D; Smyth G; Lindeman G, 2011, 'Abstract SY12-03: Getting abreast of the mammary epithelial hierarchy and breast cancer', in Cancer Research, American Association for Cancer Research (AACR), presented at Proceedings: AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011; Orlando, FL,
    Conference Papers | 2010
    Lim E; Wu D; Pal B; Bouras T; Asselin-Labat M-L; Vaillant F; Yagita H; Lindeman GJ; Smyth GK; Visvader JE, 2010, 'Abstract P4-04-03: Transcriptome Analyses of Mouse and Human Mammary Cell Subpopulations Reveals Multiple Conserved Genes and Pathways', in Cancer Research, American Association for Cancer Research (AACR), presented at Abstracts: Thirty-Third Annual CTRC‐AACR San Antonio Breast Cancer Symposium‐‐ Dec 8‐12, 2010; San Antonio, TX,
    Conference Papers | 2009
    Lim E; Vaillant F; Wu D; Forrest N; Pal B; Gyorki D; Smyth GK; Visvader J; Lindeman G, 2009, 'Investigation of human mammary stem and progenitor subpopulations from BRCA1 mutation carriers and noncarriers', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, FL, Orlando, presented at 45th Annual Meeting of the American-Society-of-Clinical-Oncology, FL, Orlando, 29 May 2009 - 02 June 2009,

2017-27

NBCF Endowed Chair (Co funded by Garvan Institute) ($5,000,000). Role CIA

2019-21

Therapeutic targeting of dual CDK4/6 inhibitor and endocrine resistant breast cancer. APP IIRS-19-054. NBCF (CIA Caldon). ($582,432) Role: CIB

2018-21

Transforming endocrine therapy for breast and prostate cancer. MNBCF Collaborative Research Initiative (CIA Tilley) ($2,500,000). Role: CID

2018-21

Pushing AR toward better outcomes in breast and prostate cancers. APP 1145777. NHMRC Project Grant (CIA Tilley) (A$1,000,000). Role: CIE

2018-21

Reactivating p53 to combat CDK4/6 inhibitor resistance in ER positive Breast Cancer. St Vincent’s Clinic Foundation ($40,000) Role: CIA.

2019-20

Targeting the p53 pathway in the age of CDK4/6 inhibitor resistant ER+ breast cancer. APP IIRS-19-053. NBCF (CIA Portman). ($197,825). Role: CIB.

2017-20

Targeting the Oncoprotein MDMX as a Novel Treatment for Triple Negative Breast Cancer. APP 1123057. NHMRC Project Grant (CIA Haupt) (A$800,000). Role: CIC

2017-20

Four dimensional epigenome remodelling: implications for endocrine resistance in breast cancer. APP 1128916. NHMRC Project Grant (CIA Clark) (A$828,559.50). Role: CIC

2017-20

The clinical significance of sex hormone crosstalk in ER+ breast cancer. APP 1130077. NHMRC Project Grant (CIA Tilley) (A$1,009,006). Role: CIC

2017-9

Evaluating ODM201, an AR degrader, in breast cancer. Bayer Pharm (A$200,000). Role CIA.

2017-9

Progesterone as an anticancer therapy in early breast cancer. RG 17-08. Cancer Council of New South Wales Project Grant (A$450,000). Role: CIA

Past

2017-8

2016-8

Metabolic effects of exercise on breast cancer. Thelma Greig Cancer Grant. St Vincent’s Clinic Foundation (A$50,000). Role: CIA.

A novel approach to overcome therapy-resistance in breast cancer. APP 1107170. Cancer Australia. (A$600,000). Role: CIA.

2016-7

Identification of breast cancer subtype-specific tumour antigens using the local immune response. NBCF (A$200,000). Role: CIA.

2016-7

Evaluating MDM2 inhibitors in breast cancer. Novartis Australia (A$51,000). Role: CIA.

2014-7

Sensitizing breast cancers to hormone receptor-directed therapies. NBCF & Victorian Cancer Agency Practitioner Fellowship (A$800,000). Role: CIA

2015-6

Targeting the p53 pathway in ER-positive breast cancer. Australia New Zealand Breast Cancer Trialist Group (A$91,600). Role: CIA.

2014-5

Evaluation of concurrent chemoendocrine therapy and predictive biomarkers for HR+ breast cancer. Ramaciotti Award, Perpetual Trustees Australia (A$75,000). Role: CIA.

2013-4

Exploiting DNA repair deficits in non BRCA mutation associated breast cancer.Cancer Research Grant, Pfizer Australia (A$50,000). Role: CIA.

2011-4

The identification of novel treatments for poor prognosis subgroups of breast cancer.NHMRC Overseas Postdoctoral Fellowship (A$360,000). Role: CIA.

2010

Fulbright Victoria Fellowship. (A$25,000). Role: CIA.

2006-9

White/Zaal PhD scholarship. NBCF (A$105,000). Role: CIA.

2008

Characterization of human mammary stem and progenitor cells. Postgraduate Research award, GlaxoSmithKline Australia (A$25,000) Role: CIA.

2007

Characterization of human mammary stem and progenitor cells. Career development award, Clinical Oncological Society of Australia (A$50,000) Role: CIA.

2017

NBCF Endowed Chair

National Breast Cancer Foundation

Breast Cancer Research

2015

Connie Johnson Award

Garvan Institute

Breast Cancer Research

2014

Ramaciotti Award

Perpetual Trustees

Translational Research

2014

NBCF Practitioner Fellowship

NBCF/ Victorian Cancer Agency

Translational Research

2013

Claudia Adams Barr Fellowship

Claudia Adams Barr Foundation

Post doctoral research

2012

AACR Scholar-In-Training Award

Susan G. Komen for the Cure®

SABCS Poster ppt

2011

Overseas Postdoctoral Fellowship

NHMRC

Post doctoral research

2010

Fulbright Victoria Scholarship

US Department of State

Post doctoral research

2009

JJ Billings Overseas Fellowship

RACP

Post doctoral research

2009

Edith Moffatt Travel Award

WEHI

2009

Best PhD Seminar 2009

WEHI

2008

Best Oral Presentation

COSA ASM

Breast stem cells

2008

Early Career Bench & Bedside Collaboration Award

Victorian Cancer Agency

Breast cancer xenografts

2008

Best Oral Presentation

Melbourne Research Week

Breast stem cells

2008

Post Graduate Research Award

GlaxoSmithKline Australia

PhD in breast stem cells

2007

Post Graduate Research Award

Australian Stem Cell Centre

Post Graduate Research

PhD in breast stem cells

2007

Director’s Art in Science Prize

WEHI

2007

Tumour Targeting Fellowship

COSA

PhD in breast stem cells

2006

White/Zaal Scholarship

NBCF, Australia

PhD in breast stem cells

My Research Supervision

  1. Allegra FreelanderPhD student. Targeting the Androgen Receptor in endocrine-resistant breast cancer.
  2. Dr Sara Wahlroos. PhD student. Defining the role of exercise and systemic therapies in breast cancer.
  3. Sarah Alexandrou. PhD student. Overcoming resistance to CDK4/6 inhibitors in breast cancer.
  4. Dr Julia Chen. PhD Student. Novel therapeutic targeting stromal and epithelial interactions in triple negative breast cancer (TNBC)

  5. Dr Katherine Manakas. PhD Student.MDM2 inhibitors for the treatment of advanced hormone receptor positive Breast Cancer

My Teaching

We supervise PhD, honours and medical students in our laboratory.

I also teach Medical Students and Physician Trainees at St Vincent's Hospital.

Completed PhD students: Dr Kee Ming Chia (2019)

Current PhD students: Allegra Freelander, Sarah Alexandrou, Dr Sarah Wahlroos

Current Oncology Fellow: Dr Julia Chen

Past Medical Students: James Williams (UNDA 2017-8), Christopher Hudson (UNDA 2018)

Past Oncology Fellows: Dr Emma Carson